[go: up one dir, main page]

EP3347012A1 - Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central - Google Patents

Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central

Info

Publication number
EP3347012A1
EP3347012A1 EP16845102.9A EP16845102A EP3347012A1 EP 3347012 A1 EP3347012 A1 EP 3347012A1 EP 16845102 A EP16845102 A EP 16845102A EP 3347012 A1 EP3347012 A1 EP 3347012A1
Authority
EP
European Patent Office
Prior art keywords
amount
pharmaceutically acceptable
acceptable salts
solvates
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16845102.9A
Other languages
German (de)
English (en)
Other versions
EP3347012A4 (fr
Inventor
Thomas N. Chase
Kathleen E. Clarence-Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chase Pharmaceuticals Corp
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of EP3347012A1 publication Critical patent/EP3347012A1/fr
Publication of EP3347012A4 publication Critical patent/EP3347012A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Definitions

  • the invention pertains to the field of the treatment of hypocholinergic disorders of the central nervous system, in particular of Alzheimer's Disease (AD), Alzheimer type dementia, Parkinson's dementia, Progressive Supranuclear Palsy (PSP), Mild Cognitive Impairment (MCI), Lewy body diseases, Frontotemporal lobe dementia (FTD), Frontotemporal lobar degeneration, Pick's disease, Post-stroke dementia, Vascular dementia, Traumatic brain injury (TBI), Senile dementia, Autism, anorexia nervosa, falls, post-operative delirium, Down Syndrome, chronic neuropathic pain, schizophrenia, Tourette syndrome, Tardive dyskinesia, Huntington's disease, Friedrich's ataxia, Cognitive Impairment associated with Multiple Sclerosis, and other disorders of the nervous system involving a deficit in acetyl-choline neurotransmission; and to a new competitive and safe treatment, a triple combination comprising a cholinergic agonist agent, a non- anticholinergic antiemetic agent and a
  • the invention proposes a combination of a muscarinic agonist which is a Muscarinic Cholinergic Receptor Agonist (MCRA), an antiemetic agent, and a muscarinic antagonist which is a non-selective, peripheral muscarinic receptor antagonist having anticholinergic activity, herein below referred to as non-selective Peripheral Anti-Cholinergic Agent (“nsPAChA").
  • MCRA Muscarinic Cholinergic Receptor Agonist
  • nsPAChA non-selective Peripheral Anti-Cholinergic Agent
  • PNS Peripheral Nervous System
  • mAChRs Muscarinic type receptors
  • Ml through M5 Five subtypes of muscarinic receptors, Ml through M5, have been identified.
  • MCRA(s) Cholinergic Receptor Agonist(s) acting on the mAChRs, including orthosteric activators and allosteric activators, in particular both allosteric agonists and positive allosteric modulators, of mAChR subtypes.
  • naAEA(s) non- anticholinergic Anti-Emetic Agent(s).
  • Non-anticholinergic refers to antiemetic medications not primarily regarded as anticholinergic agents; they are entirely devoid of anticholinergic activity or have an extremely low ability to prevent acetylcholine from acting at its cholinergic receptor sites.
  • nsPAChA(s) non-selective, peripheral Anticholinergic Agent(s) acting on the AChRs which are present in the PNS.
  • Non-selective refers to nsPAChAs, and applies to muscarinic anticholinergic agents exhibiting inhibitory activity on the mAChRs broadly across the various subtypes of muscarinic M-receptors, namely the M1-M5 receptors.
  • Peripheral refers to muscarinic anticholinergic agents and applies to anticholinergics that are largely unable (or have a limited ability) to enter the central nervous system following systemic administration, and thus do not affect brain function to a clinically appreciable degree.
  • These drugs can include both quaternary and tertiary amine anticholinergic agents, especially those having low lipid solubility.
  • Anticholinergic therapy the treatment with an anticholinergic agent of such medical conditions as gastro-intestinal cramping, nausea, retching, vomiting, fecal incontinence, bladder spasms, urinary incontinence, overactive bladder, asthma, motion sickness, muscular spasms, and smooth muscle contractive disorders; or the treatment, if any, with an anticholinergic agent of side effects caused by MCRAs, including, but not limited to gastro-intestinal cramping, nausea, retching, vomiting, fecal incontinence, diarrhea bladder spasms, urinary incontinence, overactive bladder, asthma, motion sickness, muscular spasms, and smooth muscle contractive disorders.
  • MCRAs maximum (or maximal) tolerated dose, i.e.
  • CSF Cerebrospinal Fluid
  • - "IR” Immediate Release of the active ingredient from a composition.
  • -"ER Extended Release, including sustained release, controlled release and slow release of the active ingredient from a composition by any administration route, in particular, but not limited to oral and parenteral (including transcutaneous, transdermal, intramuscular, intravenous, and subcutaneous routes).
  • Transdermal delivery administration of drug via the skin which targets, without limitation, skin tissues just under the skin, other tissues or organs under the skin, systemic circulation, and/or the central nervous system.
  • Transdermal Therapeutic System administration of drug via transdermal delivery using transdermal drug formulations and transdermal patches incorporating such transdermal drug formulations.
  • compositions and methods means that the compositions and methods include the recited elements, but do not exclude others, “comprising” is inclusive of the terms “consisting of” and “consisting essentially of”.
  • compositions may include additional steps, components or ingredients, but only if the additional steps, components or ingredients do not materially alter the basic and novel characteristics of the claimed methods and compositions.
  • consisting essentially of means that the subsequently named component(s) is necessarily included but that another unlisted ingredient(s) that does not materially affect the basic and novel properties can also be present.
  • consisting essentially of means excluding other elements of any essential significance to the combination for the intended use.
  • a composition consisting essentially of the elements as defined herein would not exclude trace contaminants and pharmaceutically acceptable carriers,
  • “pharmaceutically acceptable salt” means either a pharmaceutically acceptable acid addition salt or a pharmaceutically acceptable base addition salt of a currently disclosed compound that may be administered without any resultant substantial undesirable biological effect(s) or any resultant deleterious interaction(s) with any other component of a pharmaceutical composition in which it may be contained.
  • “combination therapy” means treating a patient with the triple combination of a cholinergic agonist agent, a non- anticholinergic antiemetic agent and a cholinergic receptor antagonist as a therapeutic platform in rotating, alternating and/or simultaneous treatment schedules. Combination therapy may include a temporal overlap of other therapeutic agents, depending on the clinical course of a given hypocholinergic disease in a subject.
  • acetylcholine Reduced levels of neurotransmitters including acetylcholine occur in dementias of the Alzheimer type. In particular, a deficit in acetylcholine-mediated transmission is thought to contribute to the cognitive and neurobehavioral abnormalities associated with these disorders. Accordingly, drugs known to augment cholinergic transmission in the CNS are the mainstay of current therapy. Other diseases of the nervous system also involve decreased cholinergic transmission and are referred to as "hypocholinergic syndromes and disorders of the Central Nervous System (CNS)".
  • CNS Central Nervous System
  • AD Alzheimer's Disease
  • AD-type dementia Progressive Supranuclear Palsy (PSP), Mild Cognitive Impairment (MCI), Lewy Body Disease dementia (LBD), Parkinson disease dementia (PDD), post-stroke dementia, vascular dementia, Traumatic Brain Injury (TBI), Senile dementia, Autism, Anorexia Nervosa, falls, post-operative delirium, Down syndrome, Tourette syndrom, tardive dyskinesia, Frontotemporal lobe dementia (FTD), Frontotemporal lobar degeneration, Pick's disease, Huntington's disease, Friedrich's ataxia, chronic neuropathic pain, schizophrenia, Cognitive Impairment associated with Multiple Sclerosis, and other disorders of the nervous system involving a deficit in acetyl-choline neurotransmission. It is well documented that schizophrenic patients experience cognitive disturbances that are not well addressed by current
  • MCRAs have been reported to dose-dependently improve the cognitive disturbances associated with schizophrenia, but the effect of MCRAs is of limited size and dose-dependent side effects prevent further increases in the MCRA doses.
  • Acetylcholinesterase inhibitors are now not only part of the standard of care for patients suffering from a dementia of the Alzheimer type, but are also widely used off-label for various other chronic often progressive hypocholinergic disorders of the nervous system.
  • AChEIs enhance acetylcholine- mediated neurotransmission. All act in the human CNS to increase and prolong the availability of acetylcholine by inhibiting its degradatory enzyme acetylcholinesterase (AChE).
  • AChEIs have been approved by the U.S.
  • Rivastigmine has also been approved for the treatment of Parkinson's disease dementia.
  • AChEIs are available in various formulations including immediate release forms such as tablets, capsules and solutions as well as rapid dissolving and extended release forms for oral administration as well as those for parenteral (e.g. transdermal) administration.
  • a second problem limiting the success of current AChEI therapy of Alzheimer type dementias is that, even at recommended amounts, AChEIs produce dose limiting adverse reactions, mainly if not exclusively, by over- stimulating peripheral cholinergic receptors of the muscarinic type. As a result, signs and symptoms of untoward gastrointestinal, pulmonary, cardiovascular, urinary, and other systems dysfunction occur.
  • AChEIs with a nsPAChA (US 8,404,701, the disclosure of which is incorporated herein by reference in its entirety) or with a non- anticholinergic antiemetic agent has been described (US 8,877,768, the disclosure of which is incorporated herein by reference in its entirety).
  • Another way to increase the cholinergic transmission in the brain is to stimulate post-synaptic cholinergic receptors by administering an agonist of the muscarinic receptors, but the results were generally disappointing.
  • the muscarinic ligand (5R,6R)-6-(3-butylthio- 1,2,5- thiadiazol-4-yl)-l-azabicyclo[3.2.1]octane (BuTAC) exhibited high affinity for muscarinic receptors, but induced vomiting that was mitigated by administration of domperidone (M.B. Andersen et al. Neuropsychopharmacology 2003; 28: 1168-1175). No trial in humans with this muscarine agonist apparently followed this study.
  • the (3R)-N-methoxyquinuclidine-3-carboximidoyl cyanide hydrochloride known as sabcomeline and described in US5,278,170, the disclosure of which is incorporated herein by reference in its entirety, is a selective Ml receptor partial agonist that was under development for the treatment of Alzheimer's disease (Loudon JM, Bromidge SM, Brown F, et al.: "SB 202026: a novel muscarinic partial agonist with functional selectivity for Ml receptors"; J PharmacolExpTher. 1997 Dec;283(3): 1059-68 - Louden 1997, the disclosure of which is incorporated herein by reference in its entirety). It was submitted to phase III clinical trials before being discontinued (R & D Focus Drug News, March 8, 2004).
  • Another MCRA the 5-[4-(hexylsulfanyl)-l,2,5-thiadiazol-3-yl]-l-methyl- 1,2,3,6-tetrahydropyridine, known as tazomeline and described in US 5,041,455, the disclosure of which is incorporated herein by reference in its entirety, acts as a nonselective muscarinic acetylcholine receptor agonist. It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but, according to Wikipedia (September 9, 2015), its "development was apparently scrapped for unknown reasons" and no sign of an effective development is known.
  • xanomeline the 3-(4-hexyloxy-l,2,5-thiadiazol-3-yl)-l- methyl-5,6-dihydro-2H-pyridine known as xanomeline and described in US 5,043,345, the disclosure of which is incorporated herein by reference in its entirety, has been disclosed as a muscarinic acetylcholine receptor agonist with reasonable selectivity for the Ml and M4 subtypes.
  • the efficacy of xanomeline, which stimulates muscarinic receptors in the brain and in the periphery was studied in patients with Alzheimer disease in a 6-month double-blind, placebo-controlled, parallel group trial.
  • xanomeline was shown to significantly improve cognitive and behavioral symptoms of Alzheimer disease (Bodick et al, 1997; Shekhar et al, 2008), but also caused dose-dependent unacceptable side effects, including bradycardia, gastrointestinal distress, excessive salivation, and sweating. Such side effects prevented the use of doses of xanomeline that could achieve maximum anti-dementia efficacy and reflect stimulation of cholinergic receptors outside the brain.
  • Xanomeline is also described in a transdermally administrable form in US
  • EUK 1001 A xanomeline fluorinated analog, the
  • xanomeline Dose-limiting adverse events attending the use of drugs that stimulate cholinergic transmission, such as xanomeline, appear to primarily reflect the excessive stimulation of peripheral cholinergic receptors, especially those of the muscarinic type (mAChRs), such that in both healthy volunteers and Alzheimer's patients many of these side effects have been reported for xanomeline; in the patient population this led to a discontinuation rate higher than 50% while the effects on cognition were not robust and mainly seen at the highest doses tested (Mirza2003).
  • mAChRs muscarinic type
  • MCRAs consisting of allosteric modulators of the Mi-muscarinic acetylcholine receptor are extensively studied and are the object of copious patent and scientific literature.
  • An improvement in the treatment of Alzheimer type dementia is attained by a combined therapy associating a non-selective, peripheral anticholinergic agent, at a dose of from 20% to 200% the current daily doses, with an AChEI, at a dose up to about 6 times the maximal recommended dose of said AChEI, as disclosed in US 8,404,701, the disclosure of which is herein incorporated by reference in its entirety.
  • a higher acetylcholinesterase inhibition in the CNS is achieved and greater relief of the symptoms of Alzheimer type dementia is enabled. This result was obtained by successfully inferring that the good dose-response obtained with the AChEIs, i.e.
  • US 8,877,768 discloses a combined therapy associating a non-anticholinergic-antiemetic agent, at a dose of from 50% to 300% the current IR daily doses, with an AChEI, at a dose up to 4 times the maximal recommended doses of said AChEI when administered alone.
  • the antiemetics which are non- anticholinergic by definition, do not interfere with both the central and peripheral therapeutic activity of the AChEIs.
  • US 8,853,219 discloses chemical compounds as muscarinic agonists that can be used to treat normal cognitive impairment that accompanies aging, or to treat disorders such as Alzheimer's disease, dementia, autism and schizophrenia; and also discloses their combination with any anticholinergic agent, including those that cross the Blood Brain Barrier (BBB) and also those that, as taught by WO 2009/120277 in the case of the AChEIs, do not cross the BBB.
  • BBB Blood Brain Barrier
  • an MCRA/antiemetic/nsPAChA combination allows the safe administration of MCRAs doses - for the MCRAs already submitted to clinical investigation - never attained heretofore.
  • said antiemetic/nsPAChA combination when concurrently or sequentially administered in combination with a MCRA, is able not only to neutralize the adverse effects that hindered the development of a muscarinic agonist for the treatment of central disorders due to a deficit of acetylcholine in the brain, but also to increase the concentrations of acetylcholine in the CNS .
  • a MCRA/antiemetic/nsPAChA combination safe administration of even high doses of a MCRA can be achieved for a patient suffering from hypocholinergic disorders of the central nervous system, such as Alzheimer's disease (AD), AD-type dementia, Progressive Supranuclear Palsy (PSP), Mild Cognitive Impairment (MCI), Lewy Body Disease dementia (LBD), Frontotemporal lobe dementia (FTD), Frontotemporal lobar degeneration, Parkinson disease dementia (PDD), post-stroke dementia, vascular dementia, Traumatic Brain Injury, Senile dementia, Autism, Anorexia Nervosa, Down syndrome, chronic neuropathic pain, Tourette syndrome, tardive dyskinesia, Pick's disease, Huntington's disease, Friedrich's ataxia, falls, post-operative delirium, schizoaffective disorders, schizophrenia, Cognitive Impairment associated with Multiple Sclerosis, and and other disorders of the nervous system involving a deficit in acetyl-choline neurotransmission.
  • the combination allows
  • the finding of the present invention represents a further progress in the treatment of hypocholinergic disorders, especially in view of the lack of efficacy of the muscarinic cholinergic receptor agonists at the doses administered to the patients and of the apparently irreducible adverse effects induced by said agonists at the administered doses.
  • the method of the present invention comprises treating a patient in need of such a treatment with a high dose of a nsPAChA, in combination with an antiemetic and a MCRA.
  • This treatment method precludes the onset of MCRA- associated peripheral dose-limiting adverse effects as well as the onset of nsPAChA central adverse effects, because these anticholinergics are substantially peripheral.
  • the present invention provides a combination comprising, as Components:
  • MCRA muscarinic cholinergic receptor agonist
  • naAEA non-anticholinergic antiemetic agent
  • nsPAChA non-selective peripheral anticholinergic agent
  • the present invention also provides a method of using the above triple combination for the treatment of hypocholinergic disorders in CNS.
  • the present invention provides the above combination wherein said Components (b) and (c) are formulated in the same unit form.
  • the (b)+(c) fixed-dose combination will also designated as “Component (b/c).
  • the present invention also provides the above triple combination, wherein said Components (a) and (c) are formulated in the same unit form.
  • the (a)+(c) fixed-dose combination will also designated as "Component (a/c)”.
  • the present inventors found that, in order to assure safe treatment of hypocholinergic disorders and sure synergy with the third component of the combination, i.e. the nsPAChA Component (c), the non- anticholinergic antiemetic agent must be administered concurrently with the MCRA from the beginning of the therapeutic treatment of a patient submitted to this cholinergic treatment for the first time.
  • said naAEA and said MCRA are preferably present in said combination as a fixed-dose combination consisting of a pharmaceutical composition wherein said naAEA and said MCRA are formulated in a dosage unit form in admixture with a pharmaceutical carrier.
  • the present invention also provides the above combination, wherein said Components (a) and (b) are formulated in the same unit form.
  • the (a)+(b) fixed-dose combination will also designated as "Component (a/b)”.
  • the novel pharmaceutical composition in dosage unit form comprising, as active ingredients, (a) a MCRA; and (b) a naAEA, in admixture with a pharmaceutical carrier or vehicle, is a particularly advantageous embodiment of the present invention.
  • a MCRA selected from the goup consisting of xanomeline and pharmaceutically acceptable salts thereof and MK-7622 and pharmaceutically acceptable salts thereof, at a dose capable of increasing the acetylcholine supply in the CNS of a patient suffering from a hypocholinergic disorder;
  • naAEA selected from the group consisting of ondansetron and pharmaceutically acceptable salts and solvates therof, domperidone and pharmaceutically acceptable salts and solvates therof, metoclopramide and pharmaceutically acceptable salts and solvates therof, in an amount of from 50% to 300% the maximum amout contained in the commercial preparations of said naAEA,
  • the present invention also provides the above combination as a fixed-dose combination wherein said Components (a), (b) and (c) are formulated in the same unit form.
  • the present invention also provides the addition of an AChEI to the above MCRA/naAEA/nsPAChA combination, thus assuring a maximum supply of acetylcholine to the CNS by the administration of a combination of the four components.
  • the fourth AChEI component will also be designated as "Component (d)".
  • kits comprising a combination selected from the group consisting of
  • naAEA in a pharmaceutical composition in a dosage unit form wherein said naAEA is in admixture with a pharmaceutical carrier
  • a fixed-dose combination comprising a MCRA and a nsPAChA in a dosage unit form wherein said MCRA and said nsPAChA are formilated together in admixture with a pharmaceutical carrier;
  • nsPAChA in a pharmaceutical composition in a dosage unit form wherein said nsPAChA is in admixture with a pharmaceutical carrier
  • a fixed dose combination comprising a MCRA and a naAEA in a dosage unit form wherein said MCRA and said naAEA are formulated together in admixture with a pharmaceutical carrier.
  • the fixed-dose combination consisting of a pharmaceutical composition comprising a MCRA and a naAEA in a dosage unit form wherein said combination is in admixture with a pharmaceutical carrier is a novel entity that is a further object of the present invention.
  • This kit which may also contain an AChEI in a pharmaceutical composition in dosage unit form wherein said AChEI is in admixture with a pharmaceutical carrier, can simplify the administration of the above combination to patients suffering from hypocholinergic disorders of the CNS, who are often not sufficiently able to manage multiple packages.
  • the present invention provides a pharmaceutical combination comprising as
  • a muscarinic receptor agonist selected from the group consisting of muscarinic cholinergic receptor agonists (MCRA);
  • a muscarinic receptor antagonist selected from the group consisting of the nonselective, peripheral anticholinergic agents (nsPAChAs).
  • said pharmaceutical combination comprises as Components:
  • said pharmaceutical combination comprises as
  • nsPAChA selected from the group consisting of oxybutynin and pharmaceutically acceptable salts thereof, in a pharmaceutical composition consisting of a TTS, in admixture with a pharmaceutical carrier.
  • said pharmaceutical combination comprises as Components:
  • composition in dosage unit form comprising
  • nsPAChA selected from the group consisting of oxybutynin and pharmaceutically acceptable salts thereof, in a pharmaceutical composition consisting of a TTS, in admixture with a pharmaceutical carrier.
  • a preferrd pharmaceutical combination comprises
  • a MCRA selected form the group consisting of cevimeline and pharmaceutically acceptable salts thereof; milameline and pharmaceutically acceptable salts thereof; xanomeline and pharmaceutically acceptable salts thereof and MK-7622 and pharmaceutically acceptable salts thereof, in a pharmaceutical composition in admixture with a pharmaceutical carrier;
  • a naAEA selected from the group consisting of ondansetron and pharmaceuticaslly acceptable salts and solvates thereof, domperidone and pharmaceutically acceptable salts and solvates thereof and metoclopramide and pharmaceutically acceptable salts and solvates thereof, in a pharmaceutical composition in admixture with a pharmaceutical carrier;
  • nsPAChA consisting of oxybutynin and pharmaceutically acceptable salts thereof, in a TTS in admixture with a pharmaceutical carrier.
  • This combination may be used for the treatment of Alzheimer type dementia and more generally for hypocholinergic disorders of the central nervous system, including Parkinson's disease dementia, Lewy Body Dementia, Frontotemporal Lobar Dementia, Mild Cognitive Impairment (MCI), Vascular Dementia, Traumatic Brain Injury, falls, post-operative delirium, Down Syndrome, Anorexia nervosa, and Schizophrenia.
  • Parkinson's disease dementia Lewy Body Dementia
  • Frontotemporal Lobar Dementia Mild Cognitive Impairment (MCI)
  • Vascular Dementia Traumatic Brain Injury, falls, post-operative delirium, Down Syndrome, Anorexia nervosa, and Schizophrenia.
  • Any MCRA which is able to cross the brain blood barrier of a human in order to stimulate the muscarinic cholinergic receptors in the CNS may be used as Component (a) according to the present invention.
  • the MCRA used as Component (a) is one of the muscarinic cholinergic agonists that have extensively, but unsuccessfully been investigated in relation to the possibility of using them for the treatment of Alzheimer type dementia, as well as Mi receptor positive allosteric modulators that are believed to be useful in the treatment of this and other diseases involving the muscarinic Mi receptor.
  • said MCRA is selected from the group consisting of 1 -methylpiperidine-4-spiro-5 ' (2' -ethyl- 1 ' ,4' -thiazoline-3 ' -one) (AF267) and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride (AF 267B) described in EP 0711292;
  • the amount of the MCRA Component (a) of the combination may vary according to intrinsic muscarinic cholinergic receptor potency of said component and is present in an amount from 1 -times to up to six times the maximum amount contained in the commercial products or ofthe maximal, single MCRA dose administered during the clinical trials of each MCRA, that is considered to be equivalent to the Maximum Tolerated Dose as determined during the clinical trials.
  • said dose is from 1.2-times to 4-times and even from 1.2-times to 6- times higher than the maximum amount contained in the commercial products or of the maximal, single MCRA dose administered during the clinical trials.
  • the MCRA Component (a) in the combination of the present invention is present in an amount from 1 -times to up to 6- times greater than the amount of MCRA Component (a) that first induces vomiting and/or diarrhea in said patient when the MCRA Component (a) is administered alone.
  • the above criteria will result in the MCRA Component (a) in the combination of the present invention being present in an amount from 0.5 mg to 1500 mg.
  • the maximum dose/unit form approved for cevimeline is 30 mg, to be administered three times per day.
  • cevimeline is the sole MCRA approved for a pharmacological treatment, said treatment having no relation with any form of dementia.
  • cevimeline as hydrochloride hemihydrate, is present in an amount of from 30 mg to 180 mg, advantageously from more than 30 mg to 180 mg, preferably from 36 mg to 180 mg;
  • milameline, as hydrochloride is present in an amount of from 2 mg to 12 mg, preferably from 2.4 mg to 12 mg, normally from more than 2 mg to 8 mg;
  • xanomeline, as free base, as oxalate or as L-tartrate is present in an amount of from 75 mg to 450 mg, preferably from 90 mg to 450 mg, normally from more than 75 mg to 180 mg;
  • MK-7622 especially as hydrochloride, methanesulfonate or fumarate, is present in an amount of from 5 mg to 270 mg, advantageously from more than 5 mg to 270 mg, normally from 15 mg to 225 mg.
  • each MCRA is formulated in a pharmaceutical composition in
  • xanomeline may be present in a pharmaceutical composition in dosage unit form, in admixture with a pharmaceutical carrier or vehicle in a TTS formulation, in particular in a patch for transdermal administration.
  • xanomeline is released from a patch in an amount giving xanomeline plasma concentrations of from 15.572ng/ml to 78.6ng/ml.
  • the safe daily dose of said MCRA may be up to six times the average maximal tolerated dose of said MCRA determined in its clinical trials when used alone, thanks to the competitive action of the MCRA and of the synergistically acting naAEA/naPAChA combination.
  • it is from 1 times to 6 times, advantageously from 1.2 times to 6 times said maximal tolerated MCRA dose or from 1 times to 6 times, advantageously from 1.2 times to 6 times the maximal daily dose of each MCRA, as previously administered alone to patients during the respective clinical trials.
  • the daily dose of cevimeline, as hydrochloride hemihydrate is in general from 90 mg to 540 mg, advantageously from more than 90 mg to 540 mg, preferably from 108 mg to 540 mg, normally from 108 mg to 360 mg;
  • the daily dose of milameline, as hydrochloride in general is from 8 mg to 48 mg, advantageously from more than 8 mg to 48 mg, preferably from 9.6 mg to 48 mg, normally from 9.6 mg to 32 mg;
  • the daily dose of xanomeline, as oxalate or L-tartrate in general is from 300 mg to 1350 mg, advantageously from more than 300 mg to 1350 mg or from 337.5 mg to 1350 mg, normally from 337.5 mg to 900 mg;
  • the daily dose of MK-7622, as hydrochloride, fumarate or methanesulfonate in general is from 5 mg to 270 mg, advantageously from more than 5 mg to 270 mg or preferably from 6 mg to 270 mg
  • Antiemetic medications commonly used to treat emesis, and not primarily regarded as anticholinergic agents, that are entirely devoid of anticholinergic activity or have an extremely low ability to prevent acetylcholine from acting at its cholinergic receptor sites in the brain may be used as Component (b) of the pharmaceutical combination of the present invention.
  • said Component (b) is a non- anticholinergic antiemetic agent selected from the group consisting of (bl) 5HT3-antagonists, (b2) DA-antagonists, (b3) HI -antagonists, (b4) cannabinoids, and (b5) NKl-antagonists.
  • Typical non-anticholinergic antiemetic agents are
  • 5-HT3 receptor antagonists such as 9-methyl-3-[(2-methyl-lH- imidazol- 1 -yl)methyl] - 1 ,2,3 ,9-tetrahydrocarbazol-4-one (ondansetron) and pharmaceutically acceptable salts and solvates thereof, in particular its hydrochloride dihydrate, described in EP 191562; 3S-ondansetron; 3R-onsdansetron; (3R)-10-oxo-8- azatricyclo[5.3.1.03,8]undec-5-yl lH-indole-3-carboxylate (dolasetron) and pharmaceutically acceptable salts and solvates thereof, in particular its monomethanesulfonate (mesylate or mesilate) monohydrate, described in EP 266730; l-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-indazole-3-carboxamide
  • DA-antagonists such as 5-chloro-l-(l-[3-(2-oxo-2,3- dihydro- 1 H-benzo [d] imidazol- 1 -yl)propyl]piperidin-4-yl)- 1 H-benzo [d] imidazol- 2(3H)-one (domperidone) and pharmaceutically acceptable salts and solvates thereof, particularly its maleate; l-[l-[4-(4-fluorophenyl)-4-oxo-butyl]-3,6-dihydro-2H- pyridin-4-yl]-3H-benzoimidazol-2-one (droperidol); 4-[4-(4-chlorophenyl)-4-hydroxy-
  • prochlorperazine and pharmaceutically acceptable salts and solvates thereof, particularly its dimaleate, dimesylate or 1,2-ethanedisulfonate (1: 1) (edisilate); dimethyl [ 1 - ( 1 OH-phenothiazin- 10-yl)prop an-2- yl] amine (promethazine) and pharmaceutically acceptable salts and solvates thereof, particularly its hydrochloride; 4-aminosalicylamide and benzamide derivatives like 4-amino-5-chloro-N-[2- (diethylamino)ethyl]-2-methoxybenzamide (metoclopramide) and pharmaceutically acceptable salts and solvates thereof such as its monohydrochloride monohydrate; 4- amino-5-bromo-N- [2-(diethylamino)ethyl] -2-methoxybenzamide (bromopride) and pharmaceutically acceptable salts and solvates thereof, particularly its monohydrochloride and its dihydrochloride monohydrate
  • HI histamine receptor antagonists such as l-[(4-chlorophenyl)- phenyl-methyl]-4-[(3-methylphenyl)methyl]piperazine (meclizine or meclozine) and pharmaceutically acceptable salts and solvates thereof, particularly its dihydrochloride monohydrate; dimethyl[l-(10H-phenothiazin-10-yl)propan-2-yl]amine (promethazine) and pharmaceutically acceptable salts and solvates thereof, particularly its hydrochloride; 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-propan-l-amine (chlorpromazine) or a salt thereof, particularly its hydrochloride; 2-chloro-10-[3-(4- methyl- 1 -piperazinyl)propyl] - 1 OH-phenothiazine (prochlorperazine) and pharmaceutically acceptable salts and
  • annabinoids such as cannabis; (6aR-trans)- 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-l-ol
  • NK1 -antagonists such as 5-[[(2R,3S)-2- [(lR)-l-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4- morpholinyl]methyl]-l,2-dihydro-3H-l,2,4-triazol-3-one (aprepitant); (2S,4S)-4-(4- Acetyl- 1 -piperazinyl)-N- [( 1R)- 1 - [3 ,5-bis(trifluoromethyl)phenyl]ethyl] -2-(4-fluoro-2- methylphenyl)-N-methyl-l-piperidinecarboxamide (casopitant);2-[3,5- bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-l- piperaz
  • NK1 -antagonists such
  • naAEAs are the compounds available in drugs for current antiemetic therapy, in particular,
  • alosetron hydrochloride available at the oral dose/unit form (in alosetron) of 0.5-1 mg;
  • dolasetron mesylate monohydrate available at the oral dose/unit form (in dolasetron) of 50-100 mg;
  • - granisetron hydrochloride available at the oral dose (in granisetron) of 1-2 mg or in a 52 cm transdermal patch containing 34.3 mg of granisetron releasing 3.1 mg of granisetron per 24 hours (herein below indicated as 23.1mg/24h";
  • ondansetron hydrochloride dihydrate available at the oral dose (in ondansetron) of 4-8 mg;
  • - palonosetron hydrochloride available at a the oral dose (in palonosetron) of 0.5 mg and i.v. dose (in palonosetron) of 0.25 mg;
  • tropisetron hydrochloride available at the oral dose (in tropisetron) of 5 mg;
  • chlorpromazine hydrochloride available at the oral dose (in chlorpromazine) of 25- 100 mg;
  • bromopride dihydrochloride monohydrate available at the oral dose (in bromopride) of 10 mg;
  • clebopride malate (1: 1), available at a oral dose (in clebopride) of 1 mg;
  • trimethobenzamide hydrochloride available at the oral dose (in trimethobenzamide) of 100 mg - meclizine (also called meclozine), available at the oral dose of 12.5-50 mg;
  • promethazine hydrochloride available at the oral dose (in promethazine) of 25 mg;
  • the non- anticholinergic antiemetic agent Component (b) is formulated in a pharmaceutical composition in admixture with a pharmaceutical carrier to be administeredin combination with the MCRA Component (a), and the nsPAChA Component (c).
  • the amount of the MCRA Component (a), sufficient to maximally alleviate disease-associated cognitive and other neurobehavioral symptoms; is illustrated in the above "The MCRAs" section.
  • the Component (b) is advantageously selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; azasetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; ondansetron and pharmaceutically acceptable salts and solvates thereof, especially its monohydrochloride dihydrate; granisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; dolasetron and pharmaceutically acceptable salts and solvates thereof, especially its monomethanesulfonate monohydrate, ramosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; tropisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; palonosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; domperidone and pharmaceutically acceptable salts and solvates thereof, especially its maleate; chlorpromazine and pharmaceutically acceptable salts and solvates thereof, especially its
  • the non-anticholinergic antiemetic agent, Component (b) is present in an amount of from 50% to 600%, normally 50% to 300%, of the amount of the said non-anticholinergic antiemetic agent contained as a sole active ingredient in the currently used brand or generic drugs.
  • Each of said typical non-anticholinergic antiemetic agents is present, in admixture with a pharmaceutical carrier or vehicle, in a pharmaceutical compositionin dosage unit form, as Component (b), in an amount ranging from 50% of the minimum amount to 600%, and in some cases beyond 600%, advantageously from 50% to 300%, normally from 100% to 300%, of the maximum amount of said typical non-anticholinergic antiemetic agent contained in the corresponding, currently used generic or brand drug for its antiemetic indication in IR form.
  • the currently used brand or generic drugs containing the maximum amount of said naAEA may be used as Component (b) of the combination of the present invention.
  • Advantageous naAEA in said Component (b) is selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron and pharmaceutically acceptable salts and solvates thereof, in particular the mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron and pharmaceutically acceptable salts and solvated
  • the non-anticholinergic antiemetic is present, in an IR unit form, in an amount ranging from 50% to 200% of the maximum amount of said antiemetic agent contained in the currently administered IR dosage unit forms for the treatment of the above-cited disorders or, in an ER unit form, in an amount ranging from 75% to 300% of the maximum amount of said antiemetic agent contained in the currently administered IR dosage unit forms for the treatment of the above-cited disorders.
  • ondansetron or a pharmaceutically acceptable salt or solvate thereof, in particular its hydrochloride dihydrate is present in an amount (in ondansetron) of from 4 mg to 16 mg per dosage unit in an IR unit form or in an amount of from 6 mg to 48 mg, preferably from 16 mg to 32 mg, in an ER unit form;
  • alosetron or a pharmaceutically acceptable salt thereof, in particular its hydrochloride is present in an amount (in alosetron) of from 0.5 mg to 2 mg per dosage unit in an IR unit form or in an amount of from 0.75 mg to 3 mg, in an ER unit form;
  • azasetron or a pharmaceutically acceptable salt thereof, in particular its hydrochloride is present in an amount of from 5 mg to 20 mg per dosage unit in an IR unit form or in an amount of from 7.5 mg to 30 mg, preferably from 10 mg to 30 mg, in an
  • Preferred Component (b) is a pharmaceutical composition in dosage unit form comprising a non- anticholinergic antiemetic agent selected from the group consisting of ondansetron and pharmaceutically acceptable salts and solvates thereof, in an amount (in ondansetron) of from 8 mg to 24 mg; granisetron and pharmaceutically acceptable salts and solvates thereof, in an amount (in granisetron) of from 1 mg to 3 mg; domperidone and pharmaceutically acceptable salts and solvates thereof, in an amount (in domperidone) of from 10 mg to 30 mg; metoclopramide and pharmaceutically acceptable salts and solvates thereof, in an amount (in metoclopramide) of from 10 mg to 30 mg; dronabinol, in an amount of from 10 mg to 30 mg; nabilone, in an amount of from 1 mg to 3 mg; aprepitant, in an amount of from 125 mg to 375 mg; netupitant, in an amount of from 300 mg to 900 mg;
  • Ondansetron may also be used as formulated in a patch, for example as described by Farsiya Fathima et al. in Research in J. Pharm. And Tech. 4,4(5), May 2011, 806-814: "Formulation and Evaluation of Matrix-Type Transdermal Delivery Systemof Ondansetron Hydrochloride Using Solvent Casting Technique", or by Cho, J., Van Duong, A., Nguyen, L.T.T. et al. in Journal of Pharmaceutical Investigation (2016). doi: 10.1007/s40005-016-0273-9, published online on 18 August 2016: "Design of transdermal matrix patch containing ondansetron".
  • nsPAChAs exhibiting inhibitory activity broadly across the various subtypes of muscarinic M-receptors, namely the M1-M5 receptors, as currently identified and are largely unable (have a limited ability) to enter the central nervous system following systemic administration and thus do not affect brain function to a clinically appreciable degree may be used as Component (c) according to the present invention.
  • These nsPAChAs include both quaternary ammonium salts, sulfonium salts and tertiary amine anticholinergic agents, especially those having low lipid solubility.
  • the 4-diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylethanoate known under its International Non-proprietary Name as oxybutynin, as free base or a pharmaceutically acceptable salt thereof, is a well-known non-selective anticholinergic medication used by oral route to relieve urinary and bladder difficulties, including frequent urination and urge incontinence and all the above references emphasize this use.
  • oxybutynin is a very good tool for administering anticholinergic therapy, but it is not "peripheral” as per the definition given above because it is able to cross the blood brain barrier (“BBB”) to a non-negligible extent (Rebecca J McCrery and Rodney A Appell, TherClin Risk Manag. Mar 2006; 2/1: 19-24).
  • BBB blood brain barrier
  • Oxybutynin is also commercially presented in a 39-cm patch system containing 36 mg of oxybutynin and releasing 3.9 mg/day oxybutynin (OXYTROL ® ).
  • This patch provides significant improvements in all the measured parameters with less systemic adverse effects, as summarized by J. Jayarajan and S. B. Radomski in a review presented on 4 December 2013: "Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life" (J. Jayarajan et al., Research and Reports in Urology 2014:6), the disclosure of which is herein incorporated by reference in its entirety.
  • oxybutynin is anyway deemed to cross the BBB owing to its high lipophilicity, neutrality, and small molecular size (C. A. Donnellan et al. BMJ 1997;315: 1363-4; R. Scheife and M. Takeda, ClinTher. 2005; 27: 144-53). the disclosure of which is herein incorporated by reference in its entirety.
  • Oxybutynin is also commercially presented (GELNIQUE ® ) in a TTS consisting of a hydroalcoholic gel containing 100 mg oxybutynin chloride per gram of gel and available in a 1 gram (1.14 ml) unit dose.
  • This TTS is deemed to have a pharmacokinetic profile similar to that of the patch delivery system, while producing lower N-desethyloxybutynin metabolite plasma concentrations (Vincent R Lucente et al.; Open Access Journal of Urology 2011/3, 35-42).
  • TTS Trigger TTS
  • oxybutynin in a hydroalcoholic gel containing 30 mg oxybutynin base per gram of gel and is available (ANTUROL ® ) in a 0.92 gram (1 mL) unit dose that contains 28 mg oxybutynin per gram of gel.
  • Anturol ® demonstrated plasma levels of oxybutynin comparable to the efficacious plasma levels observed for oral and patch therapies with lower N-desethyloxybutynin plasma levels (Anturol® Gel Summary by Antares Pharma).
  • the label for transdermal oxybutynin warns that a variety of CNS anticholinergic effects have been reported, including headache, dizziness, and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment. The label further advises that patients should be told not to drive or operate heavy machinery until they know how transdermal oxybutynin affects them. The label also advises that if a patient experiences anticholinergic CNS effects, drug discontinuation should be considered. In addition, the label states that overdosage with oxybutynin has been associated with CNS anticholinergic effects including excitation, memory loss, stupor, disorientation and agitation on awakening. Hence, based on the existing literature, and the competing action of oxybutynin and an AChEI in the CNS, the combined use of such drugs would have made memory loss a-priori material risk for the treatment of Alzheimer type dementia.
  • TTS-oxybutynin may considered, in every aspect, as a nsPAChA.
  • the nsPAChAs used as Component (c) include, but are not limited to, quaternary ammonium nsPAChAs, sulfonium nsPAChAs, (1S)-(3T?)-1- azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-l-phenyl-2(lH)-iso-quinolinecarboxylate (solifenacin) and pharmaceutically acceptable salts and solvates thereof, 1- methylpiperidin-4-yl) 2,2-di(phenyl)-2-propoxyacetate (propiverine) and pharmaceutically acceptable salts and solvates thereof, 1,4,5,6-tetrahydro-l- methylpyrimidin-2-ylmethyl a-cyclohexyl-oc-hydroxy-oc-phenylacetate (oxyphencyclimine) and pharmaceutically acceptable salts and solvates thereof, (R)- N,N-diisopropyl-3-(2-hydroxy)-
  • nsPAChAs are compounds with a duration of action of at least 6 hours, advantageously from 8 to 24 hours, more advantageously from 10 to 24 hours, preferably from 12 to 24 hours, even nsPAChAs having an appropriate duration of action corresponding to the duration of action of the concomitantly administered MCRA may be successfully used.
  • Typical quaternary ammonium nsPAChAs or sulfonium nsPAChAs are compounds of formula I R 2 C— (COO)— (X) - m R (I)
  • R is a radical selected from the group consisting of those of formulas (a)-(e)
  • A being methyl and A' being (Ci-C 4 )alkyl or 2-fluoroethyl group or A and A' forming a 1,4-butylene or 1,5-pentylene chain
  • L being hydrogen or methoxy
  • Alk and Alk' each being (Ci-C 4 )alkyl
  • Y being a bivalent radical selected from the group consisting of 1,2-ethylene, 1,3-propylene, 1,4-butylene and 2-oxa-l,3- propylene
  • the corresponding counter ion being a pharmaceutically acceptable anion, such as a chloro, bromo, iodo, tartrate, hydrogen tartrate, succinate, maleate, fumarate, sulfate, hydrogen sulfate or methylsulfate anion;
  • n and m independently, are zero or 1 ;
  • X is a (C2-C3)alkylene group
  • Ri and R 2 are each phenyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 2-thienyl and, when R is a radical (a), also each represents (Ci-C 4 )alkyl;
  • R 3 is H or OH or, only when R is a radical (a), also a COOAlk group, Alk being a (Ci-C 4 )alkyl group.
  • At least one of m and n is i.
  • nsPAChAs of formula I above useful for the treatment of Alzheimer type dementia in combination with MCRAs are
  • nsPAChAs include, but are not limited to, cimetropium bromide, otilonium bromide, prifinium bromide, timepidium bromide, scopolamine methobromide, scopolamine butylbromide, scopolamine methonitrate, isopropamide iodide, valethamate bromide, atropine methobromide, atropine methonitrate, diponium bromide, pipenzolate bromide, penthienate bromide, benactizine methobromide, diphemanil, emeprioum bromide and dibutoline sulfate.
  • nsPAChAs are the tertiary amine or quaternary ammonium compounds available in drugs for current anticholinergic therapy, in particular anisotropine methyl bromide, available with a maximum dose/unit form of 100 mg; butylscopolamine bromide, with a maximum dose/unit form of 10 mg; cimetropium bromide, with a maximum dose/unit form of 50 mg; clidinium bromide, with a maximum dose/unit form of 2.5 mg; ER fesoterodine fumarate, with a maximum dose/unit form of 8 mg; glycopyrronium bromide, with a maximum dose/unit form of 2 mg; otilonium bromide, with a maximum dose/unit form of 40 mg; oxyphencyclimine hydrochloride with a maximum dose/unit form of 10 mg: prifinium bromide, with a maximum dose/unit form of 30 mg; IR propiverine hydrochloride, with a maximum dose/unit form
  • the nsPAChA is preferably selected from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, butylscopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts, TTS-oxybutynin; and valethamate pharmaceutically acceptable salts.
  • trospium chloride which is a long-acting nsPAChA whose absorbed amount, even though poor, has an average plasma half-life of about 18 hours
  • solifenacin succinate which also has a long half-life
  • propiverine hydrochloride and the aforementioned quaternary ammonium salts thereof, and TTS- oxybutynin are particularly preferred.
  • nsPAChA Component (c) of the present invention can be formulated in pharmaceutical compositions comprising, as an active ingredient thereof, said nsPAChA in admixture with a pharmaceutical carrier.
  • Said Component (c) is present in an amount that allows the reduction of peripherally mediated adverse effects that would be caused by the administration of doses of MCRA which are higher that the maximal tolerated dose found for each of them in the clinical trials of said MCRA.
  • the amount of a nsPAChA such as of each of the aforementioned tertiary amine and quaternary ammonium nsPAChAs that is commercially available for the anticholinergic therapy, may be from 0.5 times to 8 times, generally from 0.5 to 6 times, the maximum amount contained in the IR-forms of the marketed drugs.
  • the nsPAChA amount in a compositions as IR-formulation generally is from 0.5 to 4 times, preferably from 1.2 to 4 times the maximum amount contained in the marketed drugs in IR form and the nsPAChA amount in a compositions as ER-formulation is from 0.75- times to 6-times, preferably from 1.2-times to 6-times the maximum amount contained in the marketed drugs in IR form or in an amount of from 0.75-times to 4-times, preferably from 1.2-times to 4-times the maximum amount contained in the marketed drugs in ER form.
  • the combination of the present invention comprises, as advantageous Component (c), a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 1 mg to 24 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 15 mg to 240 mg of propiverine hydrochloride; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in an amount releasing from 3.9mg/24h to 7.8mg/24h oxybutynin.
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 1 mg to 24 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salt
  • the combination of the present invention comprises, as Component (c), ansPAChA selected from the group consisting of anisotropine methylbromide, in an amount from 25 mg to 300 mg, advantageously from 60 mg to 300 mg, normally from 60 mg to 200 mg; cimetropium bromide, in an amount from 25 mg to 300 mg, advantageously from 60 mg to 300 mg, normally from 60 mg to 200 mg; clidinium bromide, in an amount from 1.25 mg to 15 mg, advantageously from 3 mg to 15 mg, normally from 3 mg to 10 mg; fesoterodine fumarate, in an amount from more than 4 mg to 480 mg, advantageously from 9.6 mg to 480 mg, normally from 9.6 mg to 320 mg; glycopyrronium bromide, in an amount from 1 mg to 16 mg, advantageously from 2.4 mg to 12 mg, normally from 2.4 mg to 8 mg; otilonium bromide, in an amount from 20 mg to 240 mg, advantageously from 48 mg to
  • propiverine hydrochloride is preferably present in an amount of from 18 mg to 90 mg in an IR-formulated composition, in admixture with a pharmaceutical carrier or in an amount of from 36 mg to 180 mg in an ER-formulated composition, in admixture with a pharmaceutical carrier.
  • trospium chloride is preferably present in an amount of from 24 mg to 80 mg in an IR-formulated composition, in admixture with a pharmaceutical carrier or in an amount of from 72 mg to 240 mg in an ER-formulated composition, in admixture with a pharmaceutical carrier and TTS-oxybutynin is preferably present in a patch delivering from 3.9mg/24h to 7.8mg/24h oxybutynin.
  • Solifenacin succinate is preferably present in an amount selected from the group consisting of from 5 mg to 60 mg, from 10 mg to 40 mg, from 12 mg to 30 mg, from 12 mg to 25 mg, and 21 mg.
  • nsPAChAs are in form of a pharmaceutical acceptable salt other than that of the corresponding, commercial nsPAChA
  • the nsPAChA amount that is present in the combination is preferably equivalent to that of said corresponding commercial nsPAChA.
  • compositions prepared using the nsPAChAs as Component (c) of the combination according to the present invention allow the administration of normally 1.2- to 4-times, but even 1.2- to 6-times the maximal tolerated dose of MCRA, as averagely determined in the clinical trials, to patients suffering of Alzheimer type dementia, without clinically significant symptoms of peripheral cholinergic system overstimulation.
  • compositions are preferably formulated in dosage unit forms for oral or parenteral, in particular transdermal, administration, wherein the active ingredient is mixed with a pharmaceutical carrier or vehicle.
  • compositions prepared using the nsPAChAs Component (c) according to the present invention are indicated in the treatment of hypocholinergic disorders in combination with a naAEA Component (b) and even high doses of a MCRA Component (a), concurrently or sequentially administered therewith, in order to improve to a greater extent said symptoms without adverse effects.
  • nsPAChAs Component (c) is in a fixed-dose combination with a naAEA Component (b), wherein said nsPAChAs Component (c) is present in an amount of from 100% to 600%, up to 800% the maximum amount contained in the commercial brand or generic products used for the anticholinergic therapy.
  • a particularly advantageous combination according to this particular embodiment is a fixed dose combination of a nsPAChA selected from the group consisting of propiverine and pharmaceutically acceptable salts thereof, in an amount corresponding to from 15 mg to 240 mg of propiverine hydrochloride, trospium pharmaceutically acceptable salts, in an amount corresponding to from 20 mg to 480 mg of trospium chloride; and glycopyrronium pharmaceutically acceptable salts corresponding to from 2 mg to 16 mg of glycopyrronium bromide, with a naAEA, in a pharmaceutical composition in admixrurewit a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of propiverine and pharmaceutically acceptable salts thereof, in an amount corresponding to from 15 mg to 240 mg of propiverine hydrochloride, trospium pharmaceutically acceptable salts, in an amount corresponding to from 20 mg to 480 mg of trospium chloride; and glycopyrronium pharmaceutically acceptable salts corresponding to from 2 mg to 16 mg of glycopyrronium bromid
  • compositions and methods for treating hypocholinergic disorders which comprises administering to a patient in need of said treatment the above-illustrated combination.
  • Component (a), Component (b) and Component (c) of the combination may be administered simultaneously or sequentially to said patient, Component (a) being indifferently administered before or after Component (b) and Component (c).
  • Components (a), Component (b) and Component (c) may also be administered by the same or a different administration route.
  • the invention further provides the above combination comprising Component (a), Component (b) and Component (c), preferably each formulated in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle, for use in the treatment of hypocholinergic disorders as herein above defined.
  • the invention may also include a fourth component, Component (d), that is an AChEI, also preferably formulated in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • Component (d) that is an AChEI, also preferably formulated in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • the present invention provides the combination of any MCRA, any naAEA and any nsPAChA as exemplified in the respective sections herein, each formulated in pharmaceutical composition in admixture with a pharmaceutical carrier.
  • the combination of the present invention may be a combination comprising or consisting essentially of
  • any of the MCRAs such as those described herein above, each in a pharmaceutical composition in dosage unit form, in admixture with a pharmaceutical carrier or vehicle, said MCRA being preferably selected from the group consisting of AF267 and pharmaceutically acceptable salts and solvates thereof; cevimeline and pharmaceutically acceptable salts and solvates thereof; EUK 1001 and pharmaceutically acceptable salts and solvates thereof; milameline and pharmaceutically acceptable salts and solvates thereof; RS-86 and pharmaceutically acceptable salts and solvates thereof; sabcomeline and pharmaceutically acceptable salts and solvates thereof; talsaclidine and pharmaceutically acceptable salts and solvates thereof; tazomeline and pharmaceutically acceptable salts and solvates thereof; xanomeline and pharmaceutically acceptable salts and solvates thereof;AC- 42 and pharmaceutically acceptable salts and solvates thereof; TBPB and pharmaceutically acceptable salts and solvates thereof; 4-Fluoro-6-methyl-l-[l- (tetra)-
  • any of the naAEA such as those described herein, each in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle, said naAEA being preferably selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof; dolasetron and pharmaceutically acceptable salts and solvates thereof; granisetron and pharmaceutically acceptable salts and solvates thereof; ondansetron and pharmaceutically acceptable salts and solvates thereof; palonosetron and pharmaceutically acceptable salts and solvates thereof; domperidone and pharmaceutically acceptable salts and solvates thereof; tropisetron and pharmaceutically acceptable salts and solvates thereof; domperidone and pharmaceutically acceptable salts and solvates thereof; haloperidol; chlorpromazine and pharmaceutically acceptable salts and solvates thereof; prochlorperazine and pharmaceutically acceptable salts and solvates thereof; metoclopramide and pharmaceutically acceptable salts and solvates thereof; bromopride and pharmaceutically acceptable salts and solv
  • each of the Components (a), (b) and (c) are in pharmaceutical composition in dosage unit form wherein each of said components is in admixture with a pharmaceutical carrier or vehicle.
  • a MCRA selected from the group consisting of cevimeline and pharmaceutically acceptable salts thereof, in an amount (in cevimeline) of from 34.5 mg to 180 mg; milameline and pharmaceutically acceptable salts thereof, in an amount (in milameline) of from 2.4 mg to 12 mg; xanomeline and pharmaceutically acceptable salts thereof, in an amount (in xanomeline) of from 90 mg to 450 mg; and MK-7622 and pharmaceutically acceptable salts thereof, in an amount (in MK- 7622) of from from 5 mg to 270 mg; in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle;
  • a naAEA selected from the group consisting of ondansetron and pharmaceuticasUy acceptable salts and solvates thereof, in an amount (in ondansetron) of fro 4 mg to 64 mg, domperidone and pharmaceutically acceptable salts and solvates thereof, in an amount, in domperidone of from 5 mg to 30 mg; and metoclopramide and pharmaceutically acceptable salts and solvates the, in an amount (in metoclopramide) of from 5 mg to 30 mg; in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle; and
  • nsPAChA consisting of oxybutynin and pharmaceutically acceptable salts thereof, in admixture with a pharmaceutical carrier or vehicle in a TTS, said TTS beig a transdermal patch releasing from 3.9mg/24h to 7.8mg/24h, preferably 3.9mg/24h oxybutynin.
  • an advantageous combination may be a combination comprising or consisting essentially of
  • a MCRA selected from the group consisting of cevimeline, cevimeline hydrochloride hemihydrate, milameline, milameline hydrochloride, xanomeline, xanomeline oxalate, xanomeline L-tartrate, racemic 3-Methyl-5-(piperidin-3-yl)- 1,2,4-oxadiazole and pharmaceutically acceptable salts and solvates thereof, S-(+)- 3-methyl-5-(piperidin-3-yl)-l,2,4-oxadiazole D-tartrate; R-(-)-3-Methyl-5- (piperidin-3-yl)-l,2,4-oxadiazole L-tartrate; MK-7622, MK-7622 hydrochloride, MK-7622 methanesulfonate and MK-7622 fumarate, in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • a preferred combination may be a combination comprising or consisting essentially of
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg; and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle;
  • naAEA in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle
  • nsPAChA in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle
  • cevimeline Component (a), as free base or hydrochloride hemihydrate, is present in an amount of from 36 mg to 180 mg; and MK- 7622, as free base, as hydrochloride, as methanesulfonate or as fumarate, is present in an amount consisting of from 5 mg to 270 mg, in particular of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg.
  • the pharmaceutical combinations of this first embodiment of the present invention are useful for the treatment of hypocholinergic disorders, and even high doses of a MCRA Component (a), may be present to improve symptoms without adverse effects to a greater extent.
  • the present invention provides a method for treating hypocholinergic disorders, which comprises administering to a patient in need of said treatment the triple combinations described herein in one embodiment.
  • Component (a), Component (b) and Component (c) of the combination may be administered simultaneously or sequentially to said patient, Component (a) being indifferently administered before or after Component (b) and Component (c).
  • Components (a), Component (b) and Component (c) may also be administered by the same or a different administration route.
  • the present invention provides a pharmaceutical combination comprising or consisting essentially of, as Components: (a) a MCRA, in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle
  • a naAEA selected from the group consisting of (bl) 5HT3-antagonists, (b2) DA- antagonists, (b3) Hl-antagonists, (b4) cannabinoids, (b5) NKl-antagonists, and the netupitant-palonosetron fixed-dose combination, in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle; and
  • Another advantageous combination is one comprising or consisting essentially of (a) a MCRA, in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • a naAEA consisting of a 5HT3 -antagonist selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, azasetron and pharmaceutically acceptable salts and solvates thereof; ondansetron and pharmaceutically acceptable salts and solvates thereof; granisetron and pharmaceutically acceptable salts and solvates thereof; dolasetron and pharmaceutically acceptable salts and solvates thereof, ramosetron and pharmaceutically acceptable salts and solvates thereof; tropisetron and pharmaceutically acceptable salts and solvates thereof; and palonosetron and pharmaceutically acceptable salts and solvates thereof, in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle; and
  • another advantageous triple combination is a combination comprising or consisting essentially of:
  • a naAEA consisting of a 5HT3 -antagonist selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron and pharmaceutically acceptable salts and solvates thereof, in particular the mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron and pharmaceutically acceptable
  • nsPAChA in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • a specific MCRA/naAEA/nsPAChA combination comprises
  • a naAEA consisting of a fixed-dose combination comprising palonosetron, in an amount of from 0.25 mg to 3 mg of palonosetron or a pharmaceutically acceptable salt thereof such as its hydrochloride and from 150 mg to 600 mg of netupitant, in admixture with a pharmaceutical carrier or vehicle in an oral IR formulation;
  • nsPAChA in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • the naAEA Component (b) preferably is a fixed-dose combination consisting of a pharmaceutical composition in dosage unit form comprising palonosetron hydrochloride, in an amount (in palonosetron) of 0.5 mg and of netupitant, in an amount of 300 mg, in admixture with a pharmaceutical carrier in an oral IR formulation.
  • another advantageous combination is a combination comprising or consisting essentially of:
  • a naAEA consisting of a DA-antagonist consisting of domperidone and pharmaceutically acceptable salts and solvates thereof such as the maleate; chlorpromazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; prochlorperazine and its salts and solvates, particularly the dimaleate and the dimesylate; promethazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; and 4-aminosalicylamide derivatives such as metoclopramide and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride monohydrate, bromopride and pharmaceutically acceptable salts and solvates thereof such as the monohydrochloride or the dihydrochloride monohydrate, alizapride and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride, and clebopride and pharmaceutically acceptable salts and solvates thereof such as the malate and the hydrochloride monohydrate; in a pharmaceutical composition in admible,
  • nsPAChA in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • a naAEA consisting of a DA-antagonist consisting of domperidone or a pharmaceutically acceptable salt thereof, in particular its maleate, in an amount (in domperidone) of from 5 mg to 20 mg per dosage unit in an IR unit form or in an amount of from 7.5 mg to 60 mg, preferably from 10 mg to 60 mg, in an ER unit form; metoclopramide or a pharmaceutically acceptable salt or solvate thereof, in particular its monohydrochloride monohydrate, in an amount (in metoclopramide) of from 5 mg to 20 mg per dosage unit in an IR unit form or in an amount of from 7.5 mg to 30 mg, preferably from 10 mg to 30 mg, in an ER unit form; alizapride or a pharmaceutically acceptable salt thereof, in particular its hydrochloride, in an amount (in alizapride) of from 25 mg to 100 mg per dosage unit in an IR unit form or in an amount of from 37.5 mg to 300 mg, preferably from 100 mg to 300 mg,
  • nsPAChA in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • a further advantageous combination according to this second embodiment is a combination comprising or consisting essentially of the following Components:
  • a naAEA consisting of a histamine HI receptor antagonists selected from the group consisting of meclizine (meclozine) and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride monohydrate; promethazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; chlorpromazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride, prochlorperazine and pharmaceutically acceptable salts and solvates thereof such as the dimaleate, the dimesylate or the 1,2-ethanedisulfonate (1: 1) (edisilate); hydroxyzine and pharmaceutically acceptable salts and solvates thereof such as the dihydrochloride or the 1,1 '-methylene bis(2-hydroxy-3- naphthalenecarboxylic acid (pamoate) salt; in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle and
  • nsPAChA in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • a further advantageous combination is a combination comprising or consisting essentially of the following Components:
  • a naAEA consisting of a histamine HI receptor antagonists selected from the group consisting of meclizine or a pharmaceutically acceptable salt thereof, in particular its hydrochloride, in an amount (in meclizine) of from 25 mg to 100 mg per dosage unit in an IR unit form or in an amount of from 37.5 mg to 150 mg, preferably from 50 mg to 150 mg, in an ER unit form; chlorpromazine or a pharmaceutically acceptable salt thereof, in particular its hydrochloride, in an amount (in chlorpromazine) of from 50 mg to 200 mg per dosage unit in an IR unit form or in an amount of from 75 mg to 300 mg, preferably from 100 mg to 300 mg, in an ER unit form; prochlorperazine or a pharmaceutically acceptable salt thereof, in particular its maleate, in an amount (in prochlorperazine) of from 2.5 mg to 10 mg per dosage unit in an IR unit form or in an amount of from 3.75 mg to 15 mg, preferably from 5 mg to 15 mg, in
  • nsPAChA in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • a preferred combination according to this second embodiment is a combination comprising or consisting essentially of the following Components:
  • a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg; domperidone and
  • the pharmaceutical combination according to this second embodiment are indicated in the treatment of hypocholinergic disorders and even high doses of a MCRA Component (a), may be present said symptoms without adverse effects to a greater extent.
  • the present invention provides a method for treating hypocholinergic disorders, which comprises administering to a patient in need of said treatment the triple combinations described according to this second embodiment.
  • Component (a), Component (b) and Component (c) of the combination may be administered simultaneously or sequentially to said patient, Component (a) being indifferently administered before or after Component (b) and Component (c).
  • Components (a), Component (b) and Component (c) may also be administered by the same or a different administration route.
  • the invention provides a pharmaceutical combination comprising or consisting essentially of, as Components:
  • nsPAChA selected form the group consisting of quaternary ammonium nsPAChAs, sulfonium nsPAChAs, solifenacin and pharmaceutically acceptable salts and solvates thereof, propiverine and pharmaceutically acceptable salts and solvates thereof, oxyphencyclimine and pharmaceutically acceptable salts and solvates thereof, tolterodine and pharmaceutically acceptable salts and solvates thereof, fesoterodine and pharmaceutically acceptable salts and solvates thereof; and TTS-oxybutynin and pharmaceutically acceptable salts thereof, in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • another combination is a combination comprising or consisting essentially of
  • a MCRA in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle
  • a naAEA in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle
  • - R is a radical selected from the group consisting of those of formulas (a)-(e)
  • A being methyl and A' being (Ci-C 4 )alkyl or 2-fluoroethyl group or A and A' forming a 1,4-butylene or 1,5-pentylene chain
  • L being hydrogen or methoxy
  • Alk and Alk' each being (Ci-C 4 )alkyl
  • Y being a bivalent radical selected from the group consisting of 1,2-ethylene, 1,3-propylene, 1,4-butylene and 2-oxa-l,3- propylene
  • the corresponding counter ion being a pharmaceutically acceptable anion, such as a chloro, bromo, iodo, tartrate, hydrogen tartrate, succinate, maleate, fumarate, sulfate, hydrogen sulfate or methylsulfate anion;
  • - n and m independently, are zero or 1;
  • - X is a (C2-C3)alkylene group
  • R 2 are each phenyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 2-thienyl and, when R is a radical (a), also each represents (Ci-C 4 )alkyl;
  • R 3 is H or OH or, only when R is a radical (a), also a COOAlk group, Alk being a (Ci-C 4 )alkyl group,
  • At least one of m and n is i.
  • the invention provides a combination comprising or consisting essentially of, as Components:
  • nsPAChA selected from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, butylscopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts, TTS-oxybutynin; and valethamate pharmaceutically acceptable salts.
  • said nsPAChA of said combination is selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, at a dose that is equivalent to from 1 mg to 24 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, at a dose that is equivalent to from 15 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, at a dose that is equivalent to from 5 mg to 40 mg of solifenacin succinate; trospium pharmaceutically acceptable salts, at a dose that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, at a dose of from 3.9 mg to 7.8 mg. Said doses are referred to daily administered doses.
  • the above therapeutic doses are administered in a pharmaceutical compositions comprising said nsPAChAs in admixture with a pharmaceutical carrier or vehicle.
  • this particular aspect of this third embodiment provides a pharmaceutical combination comprising:
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium
  • This combination preferably provides the MCRA Component (a) and, respectively, the naAEA Component (b) each in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle or in other fixed doses combinations, as illustrated herein below.
  • An advantageous combination according to this third embodiment is a combination comprising or consisting essentially of, as Components:
  • nsPAChA selected form the group consisting of trospium chloride, glycopyrronium bromide, cimetropium bromide, otilonium bromide, prifinium bromide, timepidium bromide, scopolamine methobromide, scopolamine butylbromide, scopolamine methonitrate, isopropamide iodide, valethamate bromide, atropine methobromide, atropine methonitrate, diponium bromide, pipenzolate bromide, penthienate bromide, benactizine methobromide, diphemanil, emeprioum bromide and dibutoline sulfate, in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • a further advantageous combination according to this third embodiment is a combination comprising or consisting essentially of, as Components:
  • nsPAChA selected from the group consisting of anisotropine methylbromide, in an amount from 25 mg to 300 mg, advantageously from 60 mg to 300 mg, normally from 60 mg to 200 mg; cimetropium bromide, in an amount from 25 mg to 300 mg, advantageously from 60 mg to 300 mg, normally from 60 mg to 200 mg; clidinium bromide, in an amount from 1.25 mg to 15 mg, advantageously from 3 mg to 15 mg, normally from 3 mg to 10 mg; fesoterodine fumarate, in an amount from more than 4 mg to 480 mg, advantageously from 9.6 mg to 480 mg, normally from 9.6 mg to 320 mg; glycopyrronium bromide, in an amount from 1 mg to 16 mg, advantageously from 2.4 mg to 12 mg, normally from 2.4 mg to 8 mg; otilonium bromide, in an amount from 20 mg to 240 mg, advantageously from 48 mg to 240 mg, normally from 48 mg to 160 mg; oxyph
  • a further advantageous combination according to this third embodiment is a combination comprising or consisting essentially of, as Components:
  • a nsPAChA selected from the group consisting of propiverine hydrochloride, in an amount of from 18 mg to 90 mg in admixture with a pharmaceutical carrier in an IR- formulated composition or in an amount of from 36 mg to 180 mg in admixture with a pharmaceutical carrier in an ER-formulated composition, trospium chloride, in an amount of from 24 mg to 80 mg, in admixture with a pharmaceutical carrier in an IR-formulated composition or in an amount of from 72 mg to 240 mg, in admixture with a pharmaceutical carrier in an ER-formulated composition; solifenacin succinate, in an amount selected from the group consisting of from 5 mg to 60 mg, from 10 mg to 40 mg, from 12 mg to 30 mg, from 12 mg to 25 mg, and 21 mg, in admixture with a pharmaceutical carrier in an IR-formulated composition and oxybutynin, in admixture with a pharmaceutical carrier in a transdermal patch releasing from 3.9mg/24h to 7.8mg/
  • Component (c) preferably is a nsPAChA selected from the group consisting of anisotropine methylbromide, in an amount of from 120 mg to 300 mg; butylscopolamine bromide, in an amount of from 12 mg to 40 mg; cimetropium bromide, in an amount of from 55 mg to 200 mg; clidinium bromide, in an amount of from 3 mg to 10 mg; fesoterodine fumarate, in an amount of from 9.6 mg to 32 mg; glycopyrronium bromide, in an amount of from 2.4 mg to 8 mg; otilonium bromide, in an amount of from 48 mg to 160 mg; oxyphencyclimine, in an amount of from 18 mg to 60 mg; prifinium bromide, in an amount of from 36 mg to 120 mg; propiverine hydrochloride IR, in an amount of from 18 mg to 90 mg; propiverine ER, in an amount of from 36 mg to l80 mg; solifenac
  • the pharmaceutical combinations according to this third embodiment are indicated in the treatment of hypocholinergic disorders and even high doses of a MCRA Component (a), may be present to improve said symptoms without adverse effects to a greater extent.
  • the invention provides a method for treating hypocholinergic disorders, which comprises administering to a patient in need of said treatment the above- illustrated combinations according to this third embodiment.
  • Component (a), Component (b) and Component (c) of the combination may be administered simultaneously or sequentially to said patient, Component (a) being indifferently administered before or after Component (b) and Component (c).
  • Components (a), Component (b) and Component (c) may also be administered by the same or a different administration route.
  • an advantageous combination may be a combination comprising or consisting essentially of
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, azasetron and pharmaceutically acceptable salts and solvates thereof; ondansetron and pharmaceutically acceptable salts and solvates thereof; granisetron and pharmaceutically acceptable salts and solvates thereof; dolasetron and pharmaceutically acceptable salts and solvates thereof, ramosetron and pharmaceutically acceptable salts and solvates thereof; tropisetron and pharmaceutically acceptable salts and solvates thereof; and palonosetron and pharmaceutically acceptable salts and solvates thereof, domperidone and pharmaceutically acceptable salts and solvates thereof such as the maleate; chlorpromazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; prochlorperazine and its salts and solvates, particularly the dimaleate and the dimesylate; promethazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; metoclo
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts; propiverine; pharmaceutically acceptable salts of propiverine; solifenacin; pharmaceutically acceptable salts of solifenacin; trospium pharmaceutically acceptable salts; and TTS-oxybutynin,in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts; propiverine; pharmaceutically acceptable salts of propiverine; solifenacin; pharmaceutically acceptable salts of solifenacin; trospium pharmaceutically acceptable salts; and TTS-oxybutynin,in admixture with a pharmaceutical carrier or vehicle.
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, azasetron and pharmaceutically acceptable salts and solvates thereof; ondansetron and pharmaceutically acceptable salts and solvates thereof; granisetron and pharmaceutically acceptable salts and solvates thereof; dolasetron and pharmaceutically acceptable salts and solvates thereof, ramosetron and pharmaceutically acceptable salts and solvates thereof; tropisetron and pharmaceutically acceptable salts and solvates thereof; and palonosetron and pharmaceutically acceptable salts and solvates thereof, domperidone and pharmaceutically acceptable salts and solvates thereof such as the maleate; chlorpromazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; prochlorperazine and its salts and solvates, particularly the dimaleate and the dimesylate; promethazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; metoclo
  • nsPAChA being preferably selected from the group consisting of anisotropine methylbromide, butylscopolamine bromide, cimetropium bromide, clidinium bromide, fesoterodine fumarate, glycopyrronium bromide, otilonium bromide, oxyphencyclimine hydrochloride, prifinium bromide, propiverine hydrochloride, solifenacin succinate, tolterodine tartrate, timepidium bromide, trospium chloride; TTS-oxybutynin and valethamate bromide; in admixture with a pharmaceutical carrier or vehicle.
  • nsPAChA being preferably selected from the group consisting of anisotropine methylbromide, butylscopolamine bromide, cimetropium bromide, clidinium bromide, fesoterodine fumarate, glycopyrronium bromide, otilonium
  • An advantageous combination according to this fourth embodiment may be a combination comprising or consisting essentially of, as Components:
  • a pharmaceutical composition comprising cevimeline, as free base or as its hydrochloride hemihydrate, in an amount of from 36 mg to 180 mg, in admixture with a pharmaceutical carrier or vehicle.
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg;
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium
  • Another advantageous combination according to this fourth embodiment may be a combination comprising or consisting essentially of, as Components:
  • a pharmaceutical composition comprising cevimeline, as free base or as its hydrochloride hemihydrate, in an amount of from 36 mg to 180 mg, in admixture with a pharmaceutical carrier or vehicle.
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg;
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of anisotropine methylbromide, in an amount of from 60 mg to 300 mg, normally from 60 mg to 200 mg; butylscopolamine bromide in an amount of from 12 mg to 60 mg, normally from 12 mg to 40; cimetropium bromide, in an amount of from 55 mg to 200 mg; clidinium bromide in an amount of from 3 mg to 15 mg, normally from 3 mg to 10 mg; fesoterodine fumarate, in an amount of from 9.6 mg to 32 mg; glycopyrronium bromide in an amount of from 2.2 to 12 mg, normally from 2.2 to 8 mg; otilonium bromide in an amount of from 48 mg to 240 mg, normally from 48 mg to 160 mg; prifinium bromide in an amount of from 36 mg to 180 mg, normally from 36 mg to 120 mg; propiverine hydrochloride, in an amount of from 18 mg to 180 mg; solifenacin succ
  • 76 22 in an amount consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg;
  • Another advantageous combination according to this fourth embodiment may be a combination comprising or consisting essentially of, as Components:
  • a pharmaceutical composition comprising cevimeline, as free base or as its hydrochloride hemihydrate, in an amount of from 36 mg to 180 mg, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg;
  • a pharmaceutical composition comprising a nsPAChA consisting of oxybutynin in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle in a patch releasing from 3.9mg/24h to 7.8mg/24h oxybutynin.
  • the pharmaceutical composition Component (a) comprises cevimeline, hydrochloride hemihydrate, in an amount of from 36 mg to 180 mg, in an IR-formulated oral composition in admixture with a pharmaceutical carrier or vehicle.
  • an advantageous MCRA/naAEA/nsPAChA combination according to the present invention may be a combination comprising or consisting essentially of
  • a pharmaceutical composition comprising xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, normally from 90 mg to 300 mg, in admixture with a pharmaceutical carrier, in admixture with a pharmaceutical carrier or vehicle; a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, azasetron and pharmaceutically acceptable salts and solvates thereof; ondansetron and pharmaceutically acceptable salts and solvates thereof; granisetron and pharmaceutically acceptable salts and solvates thereof; dolasetron and pharmaceutically acceptable salts and solvates thereof, ramosetron and pharmaceutically acceptable salts and solvates thereof; tropisetron and pharmaceutically acceptable salts and solvates thereof; and palonosetron and pharmaceutically acceptable salts and solvates thereof, domperidone and pharmaceutically acceptable salts and solvates thereof such as the maleate; chlorpromaz
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, butylscopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts, TTS-oxybutynin; and valethamate pharmaceutically acceptable salts; and TTS-oxybutynin, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of anisotropine pharmaceutically
  • Another advantageous combination according to this fifth embodiment may be a combination comprising or consisting essentially of, as Components
  • a pharmaceutical composition comprising xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, normally from 90 mg to 300 mg, in admixture with a pharmaceutical carrier, in admixture with a pharmaceutical carrieror vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, azasetron and pharmaceutically acceptable salts and solvates thereof; ondansetron and pharmaceutically acceptable salts and solvates thereof; granisetron and pharmaceutically acceptable salts and solvates thereof; dolasetron and pharmaceutically acceptable salts and solvates thereof, ramosetron and pharmaceutically acceptable salts and solvates thereof; tropisetron and pharmaceutically acceptable salts and solvates thereof; and palonosetron and pharmaceutically acceptable salts and solvates thereof, domperidone and pharmaceutically acceptable salts and solvates thereof such as the maleate; chlorpromazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; prochlorperazine and its salts and solvates, particularly the dimaleate and the dimesylate; promethazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; metoclo
  • An advantageous combination according to this fifth embodiment may be a combination comprising or consisting essentially of, as Components:
  • a pharmaceutical composition comprising xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, normally from 90 mg to 300 mg, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg;
  • nabilone in an amount of from 0.5 mg to 6 mg
  • aprepitant in an amount of from 20 mg to 750 mg
  • netupitant in an amount of from 150 mg to 1800 mg
  • rolapitant in an amount of from 30 mg to 360 mg
  • casopitant in an amount of from 25 mg to 300 mg
  • in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium
  • AnotherA-nadvantageous combination according to this fifth embodiment may be a combination comprising or consisting essentially of, as Components:
  • a pharmaceutical composition comprising xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, normally from 90 mg to 300 mg, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg;
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of anisotropine methylbromide, in an amount of from 60 mg to 300 mg, normally from 60 mg to 200 mg; butylscopolamine bromide in an amount of from 12 mg to 60 mg, normally from 12 mg to 40; cimetropium bromide, in an amount of from 25 mg to 300 mg, normally from 55 mg to 200 mg; clidinium bromide in an amount of from 3 mg to 15 mg, normally from 3 mg to 10 mg; fesoterodine fumarate, in an amount of from 9.6 mg to 32 mg; glycopyrronium bromide in an amount of from 2.2 to 12 mg, normally from 2.2 to 8 mg; otilonium bromide in an amount of from 48 mg to 240 mg, normally from 48 mg to 160 mg; prifinium bromide in an amount of from 36 mg to 180 mg, normally from 36 mg to 120 mg; propiverine hydrochloride, in an amount of from 18 mg to
  • Another advantageous combination according to this fifth embodiment may be a combination comprising or consisting essentially of, as Components:
  • a pharmaceutical composition comprising xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, normally from 90 mg to300 mg, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg;
  • promethazine in promethazine of from 12.5 mg to 150 mg; dronabinol in an amount of from 1.25 mg to 60 mg; nabilone, in an amount of from 0.5 mg to 6 mg; aprepitant, in an amount of from 20 mg to 750 mg; netupitant, in an amount of from 150 mg to 1800 mg; rolapitant, in an amount of from 30 mg to 360 mg; and casopitant, in an amount of from 25 mg to 300 mg; in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle; and
  • a pharmaceutical composition comprising a nsPAChA consisting of oxybutynin in admixture with a pharmaceutical carrier or vehicle, in a TTS consisting of a patch releasing from 3.9mg/24h to 7.8mg/24h oxybutynin.
  • the pharmaceutical composition Preferably, according to this fifth embodiment, the pharmaceutical composition
  • Component (a) comprises xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, normally from 90 mg to 300 mg, formulated with a pharmaceutical carrier for IR or ER administration.
  • a particular pharmaceutical composition according to this fifth embodiment comprises xanomeline base in admixture with a pharmaceutical carrier or vehicle for ER administration, said composition being in a patch delivering a predetermined xanomeline dose over 24 hours.
  • An advantageous predetermined xanomeline dose is released in an amount/24h giving xanomeline plasma concentrations in human of from 16.572ng/ml to 78.6ng/ml.
  • the same predetermined xanomeline dose releasing an amount/24h giving xanomeline plasma concentrations in human of from 16.572ng/ml to 78.6ng/ml may also be in a xanomeline Component (a) and oxybutynin Component (c) combination in a single TTS containing the two active ingredients in admixture each other in the same TTS or separated in the same patch in two different TTSs each delivering the aforementioned xanomeline and oxybutynin daily doses.
  • MCRA/naAEA/nsPAChA/combination may be a combination comprising or consisting essentially of (a) milameline hydrochloride, in an amount of from 2.4 mg to 12 mg, normally from 2.4 to 10 mg, in admixture with a pharmaceutical carrier or vehicle.
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, azasetron and pharmaceutically acceptable salts and solvates thereof; ondansetron and pharmaceutically acceptable salts and solvates thereof; granisetron and pharmaceutically acceptable salts and solvates thereof; dolasetron and pharmaceutically acceptable salts and solvates thereof, ramosetron and pharmaceutically acceptable salts and solvates thereof; tropisetron and pharmaceutically acceptable salts and solvates thereof; and palonosetron and pharmaceutically acceptable salts and solvates thereof, domperidone and pharmaceutically acceptable salts and solvates thereof such as the maleate; chlorpromazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; prochlorperazine and its salts and solvates, particularly the dimaleate and the dimesylate; promethazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochloride; metoclo
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, butylscopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts, TTS-oxybutynin; and valethamate pharmaceutically acceptable salts; and TTS-oxybutynin, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of anisotropine pharmaceutically
  • Another advantageous MCRA/naAEA/nsPAChA/combination may be a combination comprising or consisting essentially of
  • milameline hydrochloride in an amount of from 2.4 mg to 12 mg, normally from 2.4 to 10 mg, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron and pharmaceutically acceptable salts and solvates thereof, in particular themesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron and pharmaceutically acceptable salts and solvates thereof,
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium
  • Another advantageous MCRA/naAEA/nsPAChA/combination according to this further aspect of this sixth embodiment may be a combination comprising or consisting essentially of
  • a pharmaceutical composition comprising milameline hydrochloride, in an amount of from 2.4 mg to 12 mg, normally from 2.4 to 10 mg, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron and pharmaceutically acceptable salts and solvates thereof, in particular the mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron and pharmaceutically acceptable salts and solvates thereof,
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of anisotropine methylbromide, in an amount of from 60 mg to 300 mg, normally from 60 mg to 200 mg; butylscopolamine bromide in an amount of from 12 mg to 60 mg, normally from 12 mg to 40; cimetropium bromide, in an amount of from 55 mg to 200 mg; clidinium bromide in an amount of from 3 mg to 15 mg, normally from 3 mg to 10 mg; fesoterodine fumarate, in an amount of from 9.6 mg to 32 mg; glycopyrronium bromide in an amount of from 2.2 to 12 mg, normally from 2.2 to 8 mg; otilonium bromide in an amount of from 48 mg to 240 mg, normally from 48 mg to 160 mg; prifinium bromide in an amount of from 36 mg to 180 mg, normally from 36 mg to 120 mg; propiverine hydrochloride, in an amount of from 18 mg to 180 mg; solifenacin succ
  • Another advantageous MCRA/naAEA/nsPAChA/combination may be a combination comprising or consisting essentially of
  • a pharmaceutical composition comprising milameline hydrochloride, in an amount of from 2.4 mg to 12 mg, normally from 2.4 to 10 mg, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg;
  • promethazine in promethazine of from 12.5 mg to 150 mg; dronabinol in an amount of from 1.25 mg to 60 mg; nabilone, in an amount of from 0.5 mg to 6 mg; aprepitant, in an amount of from 20 mg to 750 mg; netupitant, in an amount of from 150 mg to 1800 mg; rolapitant, in an amount of from 30 mg to 360 mg; and casopitant, in an amount of from 25 mg to 300 mg; in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle; and
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of oxybutynin in admixture with a pharmaceutical carrier in a TTS consisting of a patch releasing from 3.9mg/24h to 7.8mg/24h oxybutynin.
  • the pharmaceutical composition Component (a) comprises a pharmaceutical composition comprising milameline. as free base or as hydrochloride, in an amount of from 2.4 mg to 12 mg, normally from 2.4 to 10 mg, formulated with a pharmaceutical carrier for IR or ER administration.
  • MCRA/naAEA/nsPAChA combination is a combination comprising or consisting essentially of
  • MK-7622 as free base, as hydrochloride, as monomethanesulfonate or as fumarate, in an amount consisting of from 5 mg to 270 mg, in particular of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, in an IR-formulated oral composition in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; azasetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; ondansetron and pharmaceutically acceptable salts and solvates thereof, especially its monohydrochloride dihydrate; granisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; dolasetron and pharmaceutically acceptable salts and solvates thereof, especially its monomethanesulfonate monohydrate; ramosetron and pharmaceutically acceptable salts and solvates thereof; tropisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; and palonosetron and pharmaceutically acceptable salts and solvates thereof,especially its hydrochloride; domperidone and pharmaceutically acceptable salts and solvates thereof such as the maleate; chlorpromazine and pharmaceutically acceptable salts and solvates thereof such as the
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, butylscopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts, TTS-oxybutynin; and valethamate pharmaceutically acceptable salts; and TTS-oxybutynin, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of anisotropine pharmaceutically
  • Another advantageous MCRA/naAEA/nsPAChA/combination according to this may be a combination comprising or consisting essentially of
  • MK-7622 as free base, as hydrochloride, as monomethanesulfonate or as fumarate, in an amount consisting of from 5 mg to 270 mg, in particular of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, in an IR-formulated oral composition in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride;azasetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; ondansetron and pharmaceutically acceptable salts and solvates thereof, especially its monohydrochloride dihydrate; granisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; dolasetron and pharmaceutically acceptable salts and solvates thereof, especially its monomethanesulfonate monohydrate; ramosetron and pharmaceutically acceptable salts and solvates thereof; tropisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; and palonosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; domperidone and pharmaceutically acceptable salts and solvates thereof such as the maleate; chlorpromazine and pharmaceutically acceptable salts and solvates thereof such as the hydrochlor
  • a pharmaceutical composition comprising a nsPAChA being preferably selected from the group consisting of anisotropine methylbromide, butylscopolamine bromide, cimetropium bromide, clidinium bromide, fesoterodine fumarate, glycopyrronium bromide, otilonium bromide, oxyphencyclimine hydrochloride, prifinium bromide, propiverine hydrochloride, solifenacin succinate, tolterodine tartrate, timepidium bromide, trospium chloride, TTS-oxybutynin and valethamate bromide; in admixture with a pharmaceutical carrier.
  • a nsPAChA being preferably selected from the group consisting of anisotropine methylbromide, butylscopolamine bromide, cimetropium bromide, clidinium bromide, fesoterodine fumarate, glycopyrronium bromid
  • MCRA/naAEA/nsPAChA/combination may be a combination comprising or consisting essentially of
  • a pharmaceutical composition comprising MK-7622, as free base, as hydrochloride, as monomethanesulfonate or as fumarate, in an amount of from 5 mg to 270 mg, in particular in an amount range selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, in particular thehydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron and pharmaceutically acceptable salts and solvates thereof, in particular the mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron and pharmaceutically acceptable salts and solvates thereof,
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium
  • Another advantageous MCRA/naAEA/nsPAChA/combination according to this aspect of this seventh embodiment may be a combination comprising or consisting essentially of
  • a pharmaceutical composition comprising MK-7622, as free base, as hydrochloride, as monomethanesulfonate or as fumarate, in an amount of from 5 mg to 270 mg, in particular in an amount range selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, in admixture with a pharmaceutical carrier;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron and pharmaceutically acceptable salts and solvates thereof, in particular the mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron and pharmaceutically acceptable salts and solvates thereof,
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of anisotropine methylbromide, in an amount of from 60 mg to 300 mg, normally from 60 mg to 200 mg; butylscopolamine bromide in an amount of from 12 mg to 60 mg, normally from 12 mg to 40; cimetropium bromide, in an amount of from 55 mg to 200 mg; clidinium bromide in an amount of from 3 mg to 15 mg, normally from 3 mg to 10 mg; fesoterodine fumarate, in an amount of from 9.6 mg to 32 mg; glycopyrronium bromide in an amount of from 2.2 to 12 mg, normally from 2.2 to 8 mg; otilonium bromide in an amount of from 48 mg to 240 mg, normally from 48 mg to 160 mg; prifinium bromide in an amount of from 36 mg to 180 mg, normally from 36 mg to 120 mg; propiverine hydrochloride, in an amount of from 18 mg to 180 mg; solifenac
  • Another advantageous MCRA/naAEA/nsPAChA/combination may be a combination comprising or consisting essentially of
  • a pharmaceutical composition comprising MK-7622, as free base, as hydrochloride or as fumarate, in an amount of from 5 mg to 270 mg, in particular in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition comprising a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg;
  • a pharmaceutical composition comprising a nsPAChA selected from the group consisting of oxybutynin in admixture with a pharmaceutical carrier or vehicle in a TTS consisting of a patch releasing from 3.9mg/24h to 7.8mg/24h, normally 3.9mg/24h, oxybutynin.
  • the pharmaceutical composition comprises the MK-7622 Component (a) in an amount of from 5 mg to 270 mg, in particular in an amount range selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, in admixture with a pharmaceutical carrier or vehicle in an oral IR or ER formulation.
  • Component (a) comprises MK-7622, as free base, as hydrochloride or as fumarate, in an amount from 6 mg to 270 mg, normally from more than 45 mg to 180 mg, in admixture with a pharmaceutical carrier or vehicle in an oral IR or ER formulation.
  • an advantageous MCRA/naAEA/nsPAChA combination may be a combination comprising or consisting essentially of
  • the naAEA and the nsPAChA may be any one of the above “The naAEA Component (b)” amd "The nsPAChA Component (c)” sections.
  • Advantageous Component (b/c) may be fixed-dose combination consisting of any one of the pharmaceutical compositions described in WO 2014/039627.
  • Component (a) may be any one of the above illustrated MCRAs, in particular cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, in a pharmaceutical composition in admixture with a pharmaceutical carrier or vehicle.
  • a particular advantageous MCRA/naAEA/nsPAChA/combination according to this embodiment may be a combination comprising or consisting essentially of
  • nsPAChA selected from the group consisting of propiverine and pharmaceutically acceptable salts thereof, in an amount corresponding to from 15 mg to 240 mg of propiverine hydrochloride, trospium pharmaceutically acceptable salts, in an amount corresponding to from 20 mg to 480 mg of trospium chloride; and glycopyrronium pharmaceutically acceptable salts corresponding to from 2 mg to 16 mg og glycopyrronium bromide,
  • said MCRA Component (a) is preferably selected from the group consisting of cevimeline and pharmaceutically acceptable salts and solvates thereof, in an amount, in cevimeline, of from 34.5 mg to 180 mg, xanomeline, and pharmaceutically acceptable salts and solvates thereof, in an amount, in xanomeline, of from 90 mg to 450 mg, milameline and pharmaceutically acceptable salts and solvates thereof, in an amount, in milameline of from 2.4 mg to 12 mg; and MK-2276 and pharmaceutically acceptable salts and solvates thereof, in an amount, in MK-7622, of from 6 mg to 270 mg,
  • Another advantageous MCRA/naAEA/nsPAChA combination according to this embodiment is a combination comprising or consisting essentially of
  • nsPAChA selected from the group consisting of solifenacin and pharmaceutically acceptable salts thereof, in an amount corresponding to from 5 mg to 60 mg; from 5 mg to 40 mg, from 12 mg to 30 mg, from 12 mg to 25 mg; and 21 mg of solifenacin succinate,
  • said MCRA Component (a) is preferably selected from the group consisting of cevimeline and pharmaceutically acceptable salts and solvates thereof, in an amount (in cevimeline, of from 34.5 mg to 180 mg, xanomeline, and pharmaceutically acceptable salts and solvates thereof, in an amount, in xanomeline, of from 90 mg to 450 mg, milameline and pharmaceutically acceptable salts and solvates thereof, in an amount, in milameline of from 2.4 mg to 12 mg; and MK-2276 and pharmaceutically acceptable salts and solvates thereof, in an amount, in MK-7622, of from 6 mg to 270 mg,
  • an advantageous MCRA/naAEA/nsPAChA combination may be a combination comprising or consisting essentially of
  • nsPAChA Component (c) in a pharmaceutiucal composition in admixtute with a pharmaceutical carrier or vehicle;
  • the MCRA Component (a) and the naAEA Component (b) may be any one of the corresponding compounds illustrated in the above "The MCRA Component (a)” and "The naAEA Component (b)".
  • An advantageous MCRA/naAEA composition in dosage unit form comprises or essentially consists of
  • a MCRA selected from the group consisting of AF267 and pharmaceutically acceptable salts and solvates thereof; cevimeline and pharmaceutically acceptable salts and solvates thereof; 3-[3-(3-(3-fluorophenyl)-2-propyn-l-ylthio)-l,2,5- thiadiazol-4-yl] - 1 ,2,5,6-tetrahydro- 1 -methylpyridine and pharmaceutically acceptable salts and solvates thereof; milameline and pharmaceutically acceptable salts and solvates thereof; RS-86 and pharmaceutically acceptable salts and solvates thereof; sabcomeline and pharmaceutically acceptable salts and solvates thereof; talsaclidine and pharmaceutically acceptable salts and solvates thereof; 5-[4-
  • naAEA selected from the group consisting of (bl) 5HT3-antagonists, (b2) DA- antagonists, (b3) Hl-antagonists, (b4) cannabinoids, (b5) NKl-antagonists, in admixture with a pharmaceutical carrier or vehicle.
  • a particularly advantageous MCRA/naAEA composition in dosage unit form comprises or essentially consists of
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg; and
  • a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg; domperidone
  • a particularly advantageous MCRA/naAEA fixed-dose conmbination consists of a transdermal patch comprising xanomeline and granisetron.
  • the nsPAChA Component (c) may be any one of the corresponding compounds illustrated in "The nsPAChA Component (c)" section, formulated in a pharmaceutical composition in a unit form or device, in admixture with a pharmaceutical carrier or vehicle.
  • a preferred composition in a unit form or device comprises a nsPAChA Component (c) selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA Component (c) selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that
  • a specific composition in a unit form or device comprises a nsPAChA Component (c) selected from the group consisting of anisotropine methylbromide, in an amount of from 60 mg to 300 mg, normally from 60 mg to 200 mg; butyl scopolamine bromide in an amount of from 12 mg to 60 mg, normally from 12 mg to 40; cimetropium bromide ⁇ in an amount of from 55 mg to 200 mg; clidinium bromide in an amount of from 3 mg to 15 mg, normally from 3 mg to 10 mg; fesoterodine fumarate 7 in an amount of from 9.6 mg to 32 mg; glycopyrronium bromide in an amount of from 2.2 to 12 mg, normally from 2.2 to 8 mg; otilonium bromide in an amount of from 48 mg to 240 mg, normally from 48 mg to 160 mg; prifinium bromide in an amount of from 36 mg to 180 mg, normally from 36 mg to 120 mg; propiverine hydrochloride ⁇ in an amount of from
  • solifenacin succinate is preferably present as Component (c) in an amount selected from the group consisting of from 5 mg to 60 mg; from 10 mg to 40 mg, from 12 mg to 30 mg, from 12 mg to 25 mg; and 21 mg.
  • any of the above MCRA/naAEA/nsPAChA combinations may contain, as a further component, Component (d), an AChEI also formulated in a pharmaceutical composition, said AChEI may include, but is not limited to, l,2,3,4-tetrahydro-9- acridinamine (tacrine) and pharmaceutically acceptable salts and solvates thereof, (+)- 2,3 -dihydro-5 ,6-dimethoxy-2- [ [ 1 -(phenylmethyl)-4-piperidinyl] methyl] - 1 H-inden- 1 - one (donepezil) and pharmaceutically acceptable salt and solvates thereof, (S)-N-Ethyl- N-methyl-3-[l-(dimethylamino)ethyl] -phenyl carbamate (rivastigmine) and pharmaceutically acceptable salts and solvates thereof, or 4aS,6R,8aS-3-methoxy-l l- methyl-4
  • rivastigmine preferably as free base or as hydrogen tartrate, available in 1.5-mg, 3-mg and 6-mg, capsules, as a 2-mg/dose oral solution, and in form of a transdermal patch releasing rivastigmine at 4.6 mg/24 hours, 9.5 mg/24 hour or 13.3 mg/24h
  • galantamine preferably as hydrobromide, available as a 4-mg/ml oral solution, in 4- mg, 8-mg and 12-mg IR-tablets and in 8-mg, 16-mg and 24-mg ER-capsules; are particularly preferred AChEIs.
  • said AChEI Component (d) may be formulated, in admixture with a pharmaceutical carrier or vehicle, in a pharmaceutical composition or device in dosage unit form or also used as a brand preparation.
  • rivastigmine may be also used by orally administering EXELON ® immediate-release 6mg-capsules or by applying one or more EXELON ® patches releasing 4.6mg/24 hours, 9.5mg/24 hours, or 13.3 mg/24 hours on the subject's skin, to daily release rivastigmine at a dose/24h of from 4.6 mg to 53.2 mg or from 19.95 to 53.2 mg, normally from 14.1 mg to 46 m, in combination with the above-illustrated MCRA/naAEA combination.
  • Donepezil hydrochloride may be also used by orally administering one or more ARICEPT ® immediate-release 5mg- or lOmg-tablets or the 23-mg tablets.
  • donepezil hydrochloride may be orally administered, in combination with the above- illustrated MCRA/naAEA combination, at a daily dose of from 5 mg to 100 mg or from 15 mg to 70 mg.
  • galantamine may be also administered as a brand preparation, for example by orally administering RAZADYNE ® immediate-release 8mg- or 12mg-tablets or RAZADYNE ® ER 8mg-, 16mg- or 24mg-capsules.
  • galantamine hydrobromide may be orally administered, in combination with the above-illustrated MCRA/naAEA combination, at a daily dose (in galantamine) of from 36 mg to 96 mg, normally at a daily dose or from 36 mg to 72 mg, preferably in an ER-form.
  • the AChEI Component (d) when included with Component (a), Component (b) and/or Component (c) as described herein, may be present in an amount of from about 100% to about 1000% of a recommended dose of Component (d) contained in a unit form used for the treatment of Alzheimer type dementia.
  • donepezil hydrochloride is generally present at a dose of from 5 mg to 98 mg, advantageously from 10 mg to 98 mg, advantageously from 15 mg to 69 mg, normally from 15 mg to 60 mg; rivastigmine, as hydrogen tartrate, is present, in a composition for oral administration, at a dose of from 6 mg to 30 mg, advantageously from 9 mg to 24 mg, normally 9 mg to 18 mg; as the free base, rivastigmine is present in patch releasing from 4.6mg/24h to 52mg/24h rivastigmine, advantageously from 9.6mg/24h to 39.9mg/24h, normally from 13.3mg/24h to 39.9mg/24h; and galantamine, as hydrobromide, is present in an amount of from 4 mg to 96 mg, advantageously from 12 mg to 96 mg, normally from 18 mg to 48 mg.
  • the AChEI Component (d) is generally present
  • the present invention also provides a pharmaceutical combination comprising or essentially consisting of, as Components, (a) a pharmaceutical composition in dosage unit form essentially consisting of a MCRA, in admixture with a pharmaceutical carrier; and
  • compositions in dosage unit form essentially consisting of a naAEA, in admixture with a pharmaceutical carrier or vehicle;
  • compositions in dosage unit form essentially consisting of a nsPAChA, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition in dosage unit form essentially consisting of an AChEI selected from the group consisting of donepezil hydrochloride in an amount of from 5 mg to 98 mg, advantageously from 15 mg to 69 mg, normally from 15 mg to 60 mg; rivastigmine, as hydrogen tartrate, in an amount, in rivastigmine, of from 1.5 mg to 30 mg, advantageously from 6 mg to 24 mg, normally from 9 mg to 18 mg; rivastigmine, as the free base, in patch releasing from 4.6mg/24h to 52mg/24h, advantageously from 9.6mg/24h to 39.9mg/24h, normally from 13.3mg/24h to 39.9mg/24h rivastigmine; and galantamine, as hydrobromide, in an amount (in galantamine) of from 4 mg to 96 mg, advantageously from 12 mg to 96 mg, normally from 18 mg to 48 mg, in admixture with a pharmaceutical carrier or vehicle.
  • the AChEI Component (d) may be combined with any MCRA Component (a), with any naAEA Component (b) and with any nsPAChA Component (c) illustrated in this section, in a quadruple combination useful for combating hypocholinergic disorders of the CNS.
  • kits or package containing a combination as described herein, accompanied by instructions for use are provided.
  • a kit of the present invention is a kit comprising a combination of medicaments for the treatment of hypocholinergic disorders of the CNS.
  • the kit allows for the maximal functional capacity and safety during the treatment of a patient with a triple combination wherein the three components may be administered concurrently or sequentially.
  • Component (a), Component (b) and Component (c) may be present in the kit all in IR or in ER form or one of the Components is in IR form and at least one of the others are in ER form, each in admixture with a pharmaceutical carrier in a composition formulated as illustrated in "The Formulations" section, according to known technologies.
  • kit according to the present invention may also comprise an AChEI Component (d), also in an IR or ER form, in admixture with a pharmaceutical carrier in a composition formulated as illustrated in "The Formulations" section below, according to known technologies.
  • AChEI Component (d) also in an IR or ER form, in admixture with a pharmaceutical carrier in a composition formulated as illustrated in "The Formulations" section below, according to known technologies.
  • the AChEI Component (d) When the AChEI Component (d) is present in the kit, it may be in a separate unit form wherein said AChEI is mixed with a pharmaceutical carrier in a pharmaceutical composition formulated in an IR or ER unit form.
  • kit of the present invention comprises
  • composition in IR or ER dosage unit form comprising or consisting essentially of a therapeutically effective amount of a MCRA in admixture with a pharmaceutical carrier or vehicle;
  • composition in IR or ER dosage unit form comprising or consisting essentially of a therapeutically effective amount of a naAEA in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition in IR or ER dosage unit form comprising or consisting essentially of a therapeutically effective amount of a nsPAChA in admixture with a pharmaceutical carrier or vehicle; for concurrent, sequential or separate administration.
  • compositions may be packaged in any manner suitable for administration to a patient suffering from a hypocholinergic disorder of the CNS dementia and the packaging is manufactured according to known technologies and completed with instructions for use clearly showing to the patient or to the caregiver how to take each of the units forms to be administered.
  • Said kit comprises a Component (a) selected among the MCRAs illustrated in the above section "The MCRAs", a Component (b) selected among the naAEAs illustrated in the above section “The naAEAs” and a Component (c) selected among the nsPAChAs illustrated in the above section "The nsPAChAs"
  • the kit of the present invention comprises
  • a MCRA selected from the group consisting of AF267 and pharmaceutically acceptable salts and solvates thereof; cevimeline and pharmaceutically acceptable salts and solvates thereof; EUK 1001 and pharmaceutically acceptable salts and solvates thereof; milameline and pharmaceutically acceptable salts and solvates thereof; RS-86 and pharmaceutically acceptable salts and solvates thereof; sabcomeline and pharmaceutically acceptable salts and solvates thereof; talsaclidine and pharmaceutically acceptable salts and solvates thereof; tazomeline and pharmaceutically acceptable salts and solvates thereof; xanomeline and pharmaceutically acceptable salts and solvates thereof; AC-42 and pharmaceutically acceptable salts and solvates thereof; TBPB and pharmaceutically acceptable salts and solvates thereof; 4-Fluoro-6-methyl-l-[l-(tetrahydro-2H- pyran-4-yl)-4-piperidinyl] - 1 ,3-dihydro-2H- benzimida
  • a naAEA selected from the group consisting of a naAEA selected from the group consisting of (bl) 5HT3-antagonists, (b2) DA-antagonists, (b3) HI -antagonists, (b4) cannabinoids, (b5) NK1 -antagonists and
  • nsPAChA selected from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, butylscopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts, TTS-oxybutynin; and valethamate pharmaceutically acceptable salts; and TTS- oxybutynin, in admixture with a pharmaceutical carrier or vehicle;
  • combination being in a fixed-dose combination formulated in admixture with a pharmaceutical carrier or vehicle for IR or ER administration.
  • Component (c) is preferably, a nsPAChA selected from the group consisting of quaternary ammonium nsPAChAs, sulfonium nsPAChAs, solifenacin and its pharmaceutically acceptable salts, propiverine and its pharmaceutically acceptable salts, oxyphencyclimine and its pharmaceutically acceptable salts, tolterodine and its pharmaceutically acceptable salts, fesoterodine and its pharmaceutically acceptable salts.
  • a nsPAChA selected from the group consisting of quaternary ammonium nsPAChAs, sulfonium nsPAChAs, solifenacin and its pharmaceutically acceptable salts, propiverine and its pharmaceutically acceptable salts, oxyphencyclimine and its pharmaceutically acceptable salts, tolterodine and its pharmaceutically acceptable salts, fesoterodine and its pharmaceutically acceptable salts.
  • the fixed-dose (a/b/c) combination illustrated in the "The Fixed Combinations" section, is administered to a patient in need of the treatment as a single unite form at the doses illustrated in said section.
  • kits of the present invention comprises
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount of from 5 mg to 270 mg; a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron and pharmaceutically acceptable salts and solvates thereof,
  • nsPAChA selected from the group consisting of propiverine and pharmaceutically acceptable salts thereof, in an amount corresponding to from 15 mg to 240 mg of propiverine hydrochloride, trospium pharmaceutically acceptable salts, in an amount corresponding to from 20 mg to 480 mg of trospium chloride; and glycopyrronium pharmaceutically acceptable salts corresponding to from 2 mg to 16 mg of glycopyrronium bromide,
  • the fixed-dose (a/b/c) combination illustrated in the "The Fixed Combinations" section is administered to a patient in need of the treatment as a single unit form at the doses illustrated in said section.
  • the invention provides a kit comprising
  • composition in dosage unit form comprising or consisting essentially of a MCRA in admixture with a pharmaceutical carrier or vehicle;
  • the nsPAChA is selectd from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, butylscopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts, TTS-oxybutynin; and valethamate pharmaceutically acceptable salts, in admixture with a pharmaceutical carrier or vehicle.
  • nsPAChA in said (b/c) fixed-dose combination of said kit is selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, at a dose that is equivalent to from 1 mg to 24 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, at a dose that is equivalent to from 15 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, at a dose that is equivalent to from 5 mg to 40 mg of solifenacin succinate; trospium pharmaceutically acceptable salts, at a dose that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, at a dose of from 3.9 mg to 7.8 mg. Said doses are referred to daily administered doses.
  • kits have the advantage of allowing an improvement in the treatment of a patient suffering from a hypocholinergic disorder.
  • the kit of the present invention allows the administration of a composition (b/c) comprising a naAEA and a nsPAChA that may be administered once a day, thus rendering the treatment easier for the patient or for the caregiver.
  • the naAEA and the nsPAChA present in said composition act synergistically thus allowing for an increase of the M 2 -antagonist dose.
  • kit according to this second embodiment may comprise:
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a MCRA selected from the group consisting of l-methylpiperidine-4- spiro-5'(2'-ethyl- ,4'-thiazoline-3'-one) (AF267) and pharmaceutically acceptable salts and solvates thereof; cis-2'-methylspiro ⁇ 1-azabicyclo [2.2.2] octane-3,5'-[l,3] oxathiolane ⁇ (cevimeline) and pharmaceutically acceptable salts and solvates thereof; 3-[3-(3-(3-fluorophenyl)-2-propyn- l-ylthio)- l,2,5-thiadiazol-4-yl]-l,2,5,6- tetrahydro- l-methylpyridine and pharmaceutically acceptable salts and solvates thereof; (E)-N-methoxy- 1 -( 1 -methyl- 1 ,2,5,6-tetrahydro
  • a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; azasetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride,; ondansetron and pharmaceutically acceptable salts and solvates thereof, especially its monohydrochloridedihydrate; granisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; dolasetron and pharmaceutically acceptable salts and solvates thereof, especially its monomethanesulfonate monohydrate, ramosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; tropisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; palonosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; domperidone and pharmaceutically acceptable salts and solvates thereof, especially its maleate; metoclopramide and pharmaceutically acceptable salts and solvates thereof,
  • nsPAChA selected from the group consisting of quaternary ammonium nsPAChAs, sulfonium nsPAChAs, (lS)-(3tf)-l-azabicyclo[2.2.2]oct-3-yl 3,4- dihydro-l-phenyl-2(lH)-iso-quinolinecarboxylate (solifenacin) and its pharmaceutically acceptable salts, l-methylpiperidin-4-yl) 2,2-di(phenyl)-2- propoxyacetate (propiverine) and its pharmaceutically acceptable salts, 1,4,5,6- tetrahydro- 1 -methylpyrimidin-2-ylmethyl oc-cyclohexyl-oc-hydroxy-oc- phenylacetate (oxyphencyclimine) and its pharmaceutically acceptable salts, (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine (
  • kit of this second embodiment may comprise:
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg,
  • a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg; domperidone and
  • nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h,
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, in admixture with a pharmaceutical carrier or vehicle; and
  • a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg; domperidone and
  • chlorpromazine hydrochloride in an amount (in chlorpromazine) of from 12.5 mg to 600 mg; prochlorperazinedimaleate, in an amount (in prochlorperazine) of from 2.5 mg to 30 mg; metoclopramide monohydrochloride monohydrate, in an amount (in metoclopramide) of from 5 mg to 60 mg; bromopride monohydrochloride or dihydrochloride monohydrate, in an amount (in bromopride) of from 5 mg to 60 mg; clebopride hydrogen malate or hydrochloride monohydrate, in an amount (in clebopride) of from 0.25 mg to 3 mg; levosulpiride, in an amount of from 12.5 mg to 600 mg; alizapride hydrochloride, in an amount (in alizapride) of from 25 mg to 300 mg; trimethobenzamide monohydrochloride, in an amount (in trimethobenzamide) of from 50 mg to 600 mg; mecliz
  • a nsPAChA selected from the group consisting of anisotropine methylbromide, in an amount of from 120 mg to 400 mg; butylscopolamine bromide, in an amount of from 12 mg to 40 mg; cimetropium bromide, in an amount of from 55 mg to 200 mg; clidinium bromide, in an amount of from 3 mg to 10 mg; fesoterodine fumarate, in an amount of from 9.6 mg to 32 mg; glycopyrronium bromide, in an amount of from 2.4 mg to 8 mg; otilonium bromide, in an amount of from 48 mg to 160 mg; oxyphencyclimine, in an amount of from 18 mg to 60 mg; prifinium bromide, in an amount of from 36 mg to 120 mg; propiverine hydrochloride IR, in an amount of from 18 mg to 90 mg; solifenacin succinate, in an amount selected from the group consisting of from 5 mg to 60 mg, from 10 mg to 40 mg,
  • glycopyrronium pharmaceutically acceptable salts especially the bromide, trospium pharmaceutically acceptable salts, especially the chloride, propiverine and its pharmaceutically acceptable addition salts, especially the hydrochloride
  • solifenacin its pharmaceutically acceptable addition salts, especially the succinate.
  • compositions comprising or consisting essentially of, for example:
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a MCRA consisting of MK 7622 free base, as MK 7622 hydrochloride, MK 7622 fumarate and MK 7622 methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, in admixture with a pharmaceutical carrier or vehicle; and
  • naAEA consisting of ondansetron hydrochloride dihydrate, in an amount (in ondansetron of from 4 mg to 24 mg , preferably from 8 mg to 24 mg; and
  • a nsPAChA consisting of solifenacin succinate, in an amount selected from the group consisting of from 5 mg to 60 mg, from 10 mg to 40 mg, from 12 mg to 30 mg, from 12 mg to 25 mg, and 21 mg,
  • the invention provides a kit comprising (a/c) a fixed-dose combination that is a pharmaceutical composition comprising or consisting essentially of
  • composition in dosage unit form comprising or consisting essentially of a naAEA in admixture with a pharmaceutical carrier or vehicle.
  • a MCRA selected from the group consisting of l-methylpiperidine-4-spiro- 5'(2'-ethyl- ,4'-thiazoline-3'-one) (AF267) and pharmaceutically acceptable salts and solvates thereof; cis-2'-methylspiro ⁇ 1-azabicyclo [2.2.2] octane-3,5'-
  • [1,3] oxathiolane ⁇ (cevimeline) and pharmaceutically acceptable salts and solvates thereof; 3-[3-(3-(3-fluorophenyl)-2-propyn-l-ylthio)- l,2,5-thiadiazol- 4-yl]-l,2,5,6-tetrahydro- l-methylpyridine and pharmaceutically acceptable salts and solvates thereof; (E)-N-methoxy-l-(l-methyl- l,2,5,6- tetrahydropyridin-3-yl)methanimine (milameline) and pharmaceutically acceptable salts and solvates thereof; 2-ethyl-8-methyl-2,8-diazaspiro[4.5] decane- l,3-dione (RS-86) and pharmaceutically acceptable salts and solvates thereof; (3 ?)-N-methoxyquinuclidine-3-carboximidoyl cyanide (sabcomeline) and pharmaceutically acceptable
  • nsPAChA selected from the group consisting of anisotropine pharmaceutically acceptable salts, butylscopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts and valethamate pharmaceutically acceptable salts,
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; azasetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride,; ondansetron and pharmaceutically acceptable salts and solvates thereof, especially its monohydrochloride dihydrate; granisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; dolasetron and pharmaceutically acceptable salts and solvates thereof, especially its monomethanesulfonate monohydrate, ramosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; tropisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; palonosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; domperidone and pharmaceutically acceptable salts and solvates thereof, especially its maleate; metoclo
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, and
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h,
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron)
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg, and
  • a nsPAChA selected from the group consisting of anisotropine methylbromide, in an amount of from 120 mg to 400 mg; butylscopolamine bromide, in an amount of from 12 mg to 40 mg; cimetropium bromide, in an amount of from 55 mg to 200 mg; clidinium bromide, in an amount of from 3 mg to 10 mg; fesoterodine fumarate, in an amount of from 9.6 mg to 32 mg; glycopyrronium bromide, in an amount of from 2.4 mg to 8 mg; otilonium bromide, in an amount of from 48 mg to 160 mg; oxyphencyclimine, in an amount of from 18 mg to 60 mg; prifinium bromide, in an amount of from 36 mg to 120 mg; propiverine hydrochloride IR, in an amount of from 18 mg to 90 mg; solifenacin succinate, in an amount selected from the group consisting of from 5 mg to 60 mg, from 10 mg to 40 mg,
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron
  • a MCRA selected from the group consisting of xanomeline and pharmaceutically acceptable salts and solvates thereof
  • nsPAChA selected from the group consisting of oxybutynin and pharmaceutically acceptable salts and solvates thereof
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; azasetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; ondansetron and pharmaceutically acceptable salts and solvates thereof, especially its monohydrochloridedihydrate; granisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; dolasetron and pharmaceutically acceptable salts and solvates thereof, especially its monomethanesulfonate monohydrate, ramosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; tropisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; palonosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; domperidone and pharmaceutically acceptable salts and solvates thereof, especially its maleate; me
  • a MCRA selected from the group consisting of xanomeline and pharmaceutically acceptable salts and solvates thereof
  • nsPAChA selected from the group consisting of oxybutynin and pharmaceutically acceptable salts and solvates thereof
  • oxybutynin and xanomeline TTS in admixture with a pharmaceutical carrier or vehicle in an oxybutynin and xanomeline TTS, preferably a transdermal patch, wherein said oxybutynin is released in an amount of from 3.9mg/24h to 5.85mg/24h; and said xanomeline is released in an amount/24h giving xanomeline plasma concentrations in human of from 16.572ng/ml to 78.6ng/ml; and
  • a pharmaceutical composition in dosage unit form comprising or essentially consisting of a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron)
  • the present invention provides a pharmaceutical composition in dosage unit form comprising or consisting essentially of
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle.
  • glycopyrronium pharmaceutically acceptable salts in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide
  • propiverine and pharmaceutically acceptable salts thereof in an amount that is equivalent to
  • the present invention provides a pharmaceutical composition in dosage unit form according to the present invention comprises or consists essentially of
  • nsPAChA selected from the group consisting of
  • - propiverine hydrochloride in an amount of from 18 mg to 120 mg
  • - solifenacin succinate in an amount selected from the group consisting of from 5 mg to 60 mg, from 10 mg to 40 mg, from 12 mg to 30 mg, from 12 mg to 25 mg, and 21 mg;
  • the above component (i) of the pharmaceutical composition in dosage unit form comprises or consists essentially of
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg.
  • the present invention provides a pharmaceutical composition in dosage unit form comprising or consisting essentially of
  • a MCRA selected from the group consisting of xanomeline and pharmaceutically acceptable salts and solvates thereof
  • nsPAChA selected from the group consisting of oxybutynin and pharmaceutically acceptable salts and solvates thereof
  • xanomeline in admixture with a pharmaceutical carrier or vehicle in a patch from which said oxybutynin is released in an amount of from 3.9mg/24h to 5.85mg/24h; and said xanomeline is released in an amount/24h giving xanomeline plasma concentrations in human of from 16.572ng/ml to 78.6ng/ml.
  • the invention provides a kit comprising (a/b) a novel fixed-dose combination that is a pharmaceutical composition in dosage unit form comprising or consisting essentially of
  • composition in dosage unit form comprising or consisting essentially of a nsPAChA in admixture with a pharmaceutical carrier.
  • a MCRA selected from the group consisting of l-methylpiperidine-4-spiro- 5'(2'-ethyl- ,4'-thiazoline-3'-one) (AF267) and pharmaceutically acceptable salts and solvates thereof; cis-2'-methylspiro ⁇ 1-azabicyclo [2.2.2] octane-3,5'- [1,3] oxathiolane ⁇ (cevimeline) and pharmaceutically acceptable salts and solvates thereof; 3-[3-(3-(3-fluorophenyl)-2-propyn-l-ylthio)- l,2,5-thiadiazol- 4-yl]-l,2,5,6-tetrahydro- l-methylpyridine and pharmaceutically acceptable salts and solvates thereof; (E)-N-methoxy-l-(l-methyl- l,2,5,6- tetrahydropyridin-3-yl)methanimine (milameline) and pharmaceutically
  • a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; azasetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; ondansetron and pharmaceutically acceptable salts and solvates thereof, especially its monohydrochloride dihydrate; granisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; dolasetron and pharmaceutically acceptable salts and solvates thereof, especially its monomethanesulfonate monohydrate, ramosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; tropisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; palonosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; domperidone and pharmaceutically acceptable salts and solvates thereof, especially its maleate; metoclopramide and pharmaceutically acceptable salts and solvates thereof, especially its
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a nsPAChA selected from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, butylscopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts and valethamate pharmaceutically acceptable salts, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, buty
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg; and
  • a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg; domperidone and
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle.
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from
  • kits comprising: (a/b) a fixed-dose combination that is a pharmaceutical composition comprising or consisting essentially of
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg; and
  • a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg; domperidone and
  • a pharmaceutical composition in dosage unit form comprising or consisting essentially of a nsPAChA selected from the group consisting of anisotropine methylbromide in an amount of from 25 mg to 400 mg, normally from 25 mg to 300 mg; butylscopolamine bromide, in an amount of from 5 mg to 60 mg, normally from 12 mg to 40 mg; cimetropium bromide, in an amount of from 25 mg to 200 mg, normally from 55 mg to 200 mg; clidinium bromide, in an amount of from 1.25 mg to 15 mg, normally from 3 mg to 10 mg; fesoterodine fumarate, in an amount of from 4 mg to 48 mg, normally from 9.6 mg to 32 mg; glycopyrronium bromide, in an amount of from 1 mg to 12 mg, normally from 2.4 mg to 8 mg; otilonium bromide, in an amount of from 20 mg to 240 mg, normally from 48 mg to 160 mg; oxyphencyclimine, in an amount of from 10 mg to 60 mg.
  • prifinium bromide in an amount of from 15 mg to 180 mg, normally from 36 mg to 120 mg
  • propiverine hydrochloride in an amount of from 7.5 to 180 mg, normally from 18 mg to 90 mg
  • solifenacin succinate in an amount selected from the group consisting of from 5 mg to 60 mg, from 10 mg to 40 mg, from 12 mg to 30 mg, from 12 mg to 25 mg, and 21 mg
  • tolterodine tartrate in an amount of from 1 mg to 16 mg, normally from 4.8 mg to 16 mg
  • timepidium bromide in an amount of from 7.5 mg to 180 mg, normally from 36 mg to 120 mg
  • trospium chloride in an amount of from 24 mg to 480 mg, normally from 24 mg to 240 mg
  • TTS-oxybutynin as a patch releasing from 3.9mg/24 to 7.8mg/24h, advantageously from 3.9mg/24h to 5.85mg/24h, normally 3.9mg/24h oxybut
  • the kit of the present invention comprises each of the drugs making up the composition of the invention, along with instructions for use.
  • each of the drug components of the combination may be combined into a single administrable dosage form such as a capsule.
  • Said kit may include one or more tablets, hard or soft capsules containing the Component (a) and Component (b), in the dosage amounts within the ranges described above.
  • Component (a/b) of the kits of this fourth embodiment consisting of pharmaceutical composition in dosage unit form comprising, as active ingredient, a combination with a MCRA and of a naAEA is novel and a further object of the present invention.
  • the present invention further provides a pharmaceutical composition in dosage unit form comprising or consisting essentially of
  • An advantageous MCRA/naAEA composition in dosage unit form comprises or essentially consists of (a) a MCRA selected from the group consisting of AF267 and pharmaceutically acceptable salts and solvates thereof; cevimeline and pharmaceutically acceptable salts and solvates thereof; 3-[3-(3-(3-fluorophenyl)-2-propyn-l-ylthio)-l,2,5- thiadiazol-4-yl] - 1 ,2,5,6-tetrahydro- 1 -methylpyridine and pharmaceutically acceptable salts and solvates thereof; milameline and pharmaceutically acceptable salts and solvates thereof; RS-86 and pharmaceutically acceptable salts and solvates thereof; sabcomeline and pharmaceutically acceptable salts and solvates thereof; talsaclidine and pharmaceutically acceptable salts and solvates thereof; 5-[4- (hexylsulfanyl)-l,2,5-thiadiazol-3-yl]-l-methyl-l,2,3,6
  • a naAEA selected from the group consisting of (bl) 5HT3-antagonists, (b2) DA- antagonists, (b3) Hl-antagonists, (b4) cannabinoids, and (b5) NKl-antagonists, in admixture with a pharmaceutical carrier or vehicle.
  • a particularly advantageous MCRA/naAEA composition in dosage unit form comprises or essentially consists of
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg; and
  • a naAEA selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg; domperidone and
  • solifenacin succinate when present as Component (c), preferably is in an amount selected from the group consisting of from 5 mg to 60 mg, from 10 mg to 40 mg, from 12 mg to 30 mg, from 12 mg to 25 mg, and 21 mg.
  • each of the above kits may comprise, as a further component of the combinations contained therein, Component (d), an AChEI also formulated in a pharmaceutical composition, said AChEI being selected from the group consisting of l,2,3,4-tetrahydro-9-acridinamine (tacrine) and pharmaceutically acceptable salts and solvates thereof, (+)-2,3-dihydro-5,6-dimethoxy-2-[[l- (phenylmethyl)-4-piperidinyl] methyl] - 1 H-inden- 1 -one (donepezil) and pharmaceutically acceptable salt and solvates thereof, (S)-N-Ethyl-N-methyl-3-[l- (dimethylamino)ethyl] -phenyl carbamate (rivastigmine) and pharmaceutically acceptable salts and solvates thereof, 4aS,6R,8aS-3-methoxy-l l-methyl- 4a,5,9,10,
  • donepezil hydrochloride is generally present at a dose of from 5 mg to 98 mg, advantageously from 15 mg to 69 mg, normally from 15 mg to 60 mg; rivastigmine, as hydrogen tartrate, is present, in a composition for oral administration, at a dose in rivastigmine, of from 1.5 mg to 30 mg, advantageously from 6 mg to 24 mg, normally from 9 mg to 18 mg; rivastigmine, as the free base, is present in patch releasing from 4.6mg/24h to 52mg/24h, advantageously from 9.6mg/24h to 39.9mg/24h, normally from 13.3mg/24h to 39.9mg/24h rivastigmine; and galantamine, as hydrobromide, is present in an amount of from 4 mg to 96 mg, advantageously from 12 mg to 96 mg, normally from 18 mg to 48 mg.
  • the present invention also provides a kit comprising or essentially consisting of
  • compositions in dosage unit form essentially consisting of a MCRA, in admixture with a pharmaceutical carrier or vehicle;
  • compositions in dosage unit form essentially consisting of a naAEA, in admixture with a pharmaceutical carrier or vehicle;
  • compositions in dosage unit form essentially consisting of a nsPAChA, in admixture with a pharmaceutical carrier or vehicle;
  • a pharmaceutical composition dosage unit form essentially consisting of an AChEI selected from the group consisting of donepezil hydrochloride in an amount of from 5 mg to 98 mg, advantageously from 15 mg to 69 mg, normally from 15 mg to 60 mg; rivastigmine, as hydrogen tartrate, in an amount, in rivastigmine, of from 1.5 mg to 30 mg, advantageously from 6 mg to 24 mg, normally from 9 mg to 18 mg; rivastigmine, as the free base, in patch releasing from 4.6mg/24h to 52mg/24h, advantageously from 9.6mg/24h to 39.9mg/24h, normally from 13.3mg/24h to 39.9mg/24h rivastigmine; and galantamine, as hydrobromide, in an amount (in galantamine, of from 4 mg to 96 mg, advantageously from 12 mg to 96 mg, normally from 18 mg to 48 mg, in admixture with a pharmaceutical carrier or vehicle.
  • AChEI
  • Component (d) may be combined with any MCRA Component (a) and with any naAEA Component (b) and with any nsPAChA Component (c) illustrated in this section, in a quadruple combination useful as a cocktail for combating hypocholinergic disorders of the CNS as herein above defined.
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg; and
  • a pharmaceutical composition in dosage unit form essentially consisting of a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle; and
  • a pharmaceutical composition comprising an AChEI selected from the group consisting of donepezil hydrochloride, in an amount of from 5 mg to 98 mg, advantageously from 15 mg to 69 mg, normally from 15 mg to 60 mg; rivastigmine, as hydrogen tartrate, is present, in an amount, in rivastigmine, of from 1.5 mg to 30 mg, advantageously from 6 mg to 24 mg, normally from 9 mg to 18 mg; rivastigmine, as the free base, in patch releasing from 4.6mg/24h to 52mg/24h, advantageously from 9.6mg/24h to 39.9mg/24h, normally from 13.3mg/24h to 39.9mg/24h or from 4.6mg/24h to 13.3mg/24h rivastigmine; and galantamine, as hydrobromide, in an amount (in galantamine of from 4 mg to 96 mg, advantageously from 12 mg to 96 mg, normally from 18 mg to 48 mg, in admi
  • a pharmaceutical composition in dosage unit form essentially consisting of a nsPAChA selected from the group consisting of anisotropine methylbromide, in an amount of from 25 mg to 300 mg, normally from 60 mg to 200 mg; butylscopolamine bromide in an amount of from 5 mg to 60 mg, normally from 12 mg to 40 mg; cimetropium bromide, in an amount of from 25 mg to 200 mg; clidinium bromide in an amount of from 1.25 mg to 15 mg, normally from 3 mg to 1012- mg; fesoterodine fumarate, in an amount of from 4 mg to 48 mg, normally from 9.6 mg to 32 mg; glycopyrronium bromide in an amount of from 1 mg to 12 mg, normally from 2.2 to 8 mg; otilonium bromide in an amount of from 20 mg to 240 mg, normally from 48 mg to 160 mg; prifinium bromide in an amount of from 15 mg to 180 mg, normally from 36 mg to 120 mg; propiverine hydro
  • a kit according to a preferred form of this second aspect of this fifth embodiment essentially consists of a combination of the above Components (a) and (b) with
  • a pharmaceutical composition in dosage unit form comprising or essentially consisting of the nsPAChA TTS-oxybutynin, as a patch releasing from 3.9mg/24 to 7.8mg/24h, advantageously grom 3.9mg/24h, normally 3.9mg/24h oxybutynin, in admixture with a pharmaceutical carrier or vehicle; and
  • composition in dosage unit form comprising or essentially consisting of the AChEI rivastigmine in a patch releasing from 4.6mg/24h to 39.9/mg24h, normally from 4.6mg/24h to 13.3 mg/24h rivastigmine, in admixture with a pharmaceutical carrier or vehicle.
  • a particularly preferred form of this second aspect of this fifth embodiment essentially consists of a combination of the above Component (a/b) fixed-dose combination with a Component (c/d) fixed-dose combination that is a pharmaceutical composition in dosage unit form comprising or consisting essentially of (c/d) a pharmaceutical composition essentially comsisting of
  • Said patch advantageously releases from 3.9mg/24h to 7.85mg/24h, normally
  • compositions (a/b) of the kits of the present invention described above are each novel and a further object of the present invention.
  • the invention also provides a kit comprising
  • composition in dosage unit form comprising or consisting essentially of a MCRA in admixture with a pharmaceutical carrier or vehicle;
  • a nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS -oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle; and
  • composition in dosage unit form comprising or consisting essentially of anAChEI, essentially consisting of donepezil hydrochloride, in an amount of from 5 mg to 60 mg, in admixture with a pharmaceutical carrier or vehicle
  • kits comprises, as Component (c), a nsPAChA selected from the group consisting of solifenacin succinate, in an amout of from 5 mg to 60 mg, normally from 10 mg to 25 mg or of 21 mg, propiverine hydrochloride, in an amount of from 7.5 mg to 240 mg, normally from 30 mg to 120 mg, glycopyrronium bromide, in an amount of from 1 mg to 12 mg, normally fom 2 mg to 8 mg; and trospium chloride, in an amount of from 10 mg to 480 mg, normally from 20 mg to 240 mg.
  • a nsPAChA selected from the group consisting of solifenacin succinate, in an amout of from 5 mg to 60 mg, normally from 10 mg to 25 mg or of 21 mg
  • propiverine hydrochloride in an amount of from 7.5 mg to 240 mg, normally from 30 mg to 120 mg
  • glycopyrronium bromide in an amount of from 1 mg to 12 mg, normally fom 2 mg to 8 mg
  • trospium chloride in an amount
  • the (b/c) fixed-dose combination is administered to a patient in need of the treatment as a single unit form at the doses illustrated in "The Combinations" section.
  • This kit has the advantage of allowing an improvement in the treatment of a patient suffering from a hypocholinergic disorder due to synergistic action of the antiemetic/anticholinergic combination .
  • compositions prepared by using the nsPAChAs according to the present invention are present in unit forms also containing a M 2 -antagonist that acts by presynaptically releasing acetylcholine in the CNS to improve the symptoms of Alzheimer type dementia and the other aforementioned hypocholinergic disorders.
  • MCRA muscarinic cholinergic receptor agonists
  • naAEA non-anticholinergic antiemetic agent
  • unit form will also be used to designate a “pharmaceutical composition in dosage unit form”.
  • a pharmaceutical composition of the present invention may be a composition comprising or consisting essentially of a mixture of a MCRA [Component (a)], a naAEA [Component (b)] and of a nsPAChA [Component (c)] wherein Component (a) is present in a quantity sufficient or effective to maximally alleviate disease-associated neurobehavioral symptoms for the treatment of hypocholinergic disorders, and wherein Component (b) and Component (c), the latter not appreciably penetrating the blood brain barrier, surprisingly act synergistically to attenuate the dose-limiting side effects of the MCRAs, thus enabling a greater increase in the MTD of said MCRAs with attending increase in the therapeutic efficacy of MCRAs.
  • Such a composition allows high doses of MCRA Component (a) to be safely used, that would have otherwise been dangerous in the absence of Components (b) and (c).
  • the pharmaceutical composition of the present invention improves the treatment of human hypocholinergic disorders of the CNS as described above, such as dementias of the Alzheimer type and schizophrenia.
  • any MCRA, any naAEA and any nsPAChA as described herein, and exemplified in the above "The Combinations" section may be formulated in a pharmaceutical composition in a single unit form, in admixture with at least one pharmaceutical carrier according to conventional methods in the art, and as exemplified in the "The Formulations” section below.
  • the M 2 -antagonist Component (a) is present in an amount of from 0.5 mg to 1500 mg.
  • the M 2 - antagonist Component (a) is present, in an IR-form, in an amount of from 0.5 mg to 1000 mg and in an ER-form in an amount of from 1.5 mg to 1500 mg.
  • any one of the MCRAs illustrated in the above "The MCRAs" section may be a suitable Component (a), a MCRA selected from the group consisting of AF267 and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride (AF 267B), cevimeline and pharmaceutically acceptable salts and solvates thereof, 3-[3-(3- (3-fluorophenyl)-2-propyn-l-ylthio)-l,2,5-thiadiazol-4-yl]- 1,2,5, 6-tetrahydro-l- methylpyridine (EUK 1001) and pharmaceutically acceptable salts and solvates thereof especially its oxalate, milameline and pharmaceutically acceptable salts and solvates thereof especially its hydrochloride, RS-86 and pharmaceutically acceptable salts and solvates thereof, especially its hydrobromide; sabcomeline and pharmaceutically acceptable salts and solvates thereof; talsaclidine and pharmaceutically acceptable salts and solvates thereof, especially its fuma
  • Component (a) is a MCRA selected from the group consisting of cevimeline and pharmaceutically acceptable salts thereof, milameline and pharmaceutically acceptable salts and solvates thereof, xanomeline and pharmaceutically acceptable salt and solvates thereof; racemic 3-Methyl-5-(piperidin-3- yl)-l,2,4-oxadiazole and pharmaceutically acceptable salts and solvates thereof, S-(+)- 3-methyl-5-(piperidin-3-yl)-l,2,4-oxadiazole D-tartrate; R-(-)-3-Methyl-5-(piperidin-3- yl)-l,2,4-oxadiazole L-tartrate;MK-7622 and pharmaceutically acceptable salts and solvates thereof.
  • MCRA MCRA selected from the group consisting of cevimeline and pharmaceutically acceptable salts thereof, milameline and pharmaceutically acceptable salts and solvates thereof, xanomeline and pharmaceutically acceptable salt and solvates thereof; race
  • Cevimeline its hydrochloride hemihydrate, xanomeline, its oxalate or L-tartrate and MK-7622, its hydrochloride or fumarate or methanesulfonate are the preferred Components (a) of the fixed-dose combination.
  • the Component (a) is a MCRA selected from the group consisting of
  • hydrochloride hemihydrate in an amount of from 30 mg to 120 mg, preferably from 36 mg to 120 mg in an oral IR or, as free base or as hydrochloride hemihydrate, from 36 mg to 180 mg, preferably from 45 mg to 180 mg in an oral or transdermal ER form, in particular in a TTS.
  • hydrochloride in an amount of from 2 mg to 8 mg, preferably from 2.4 mg to 8 mg in an oral IR or, as free base or as hydrochloride, from 2.4 mg to 12 mg, preferably from 3 mg to 12 mg in an oral or transdermal ER form, in particular in a TTS;
  • - xanomeline that is present, as oxalate or L-tartrate, in an amount of from 75 mg to 300 mg preferably from 90 mg to 300 mg in an oral IR form or, as free base, as oxalate or as L-tartrate, from 90 mg to 450 mg, preferably from 112.5 mg to 450 mg in an oral or transdermal ER form, in particular in a TTS - MK-7622 that is present, as free base, as hydrochloride or as fumarate, in an amount of from 5 mg to 270 mg, in particular in an amount selected from the group consisting of more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg.
  • the Component (b) of the fixed-dose combination may be a non- anticholinergic antiemetic agent selected from the group consisting of (bl) 5HT3- antagonists, (b2) DA-antagonists, (b3) Hl-antagonists, (b4) cannabinoids, (b5) NK1- antagonists.
  • a non- anticholinergic antiemetic agent selected from the group consisting of (bl) 5HT3- antagonists, (b2) DA-antagonists, (b3) Hl-antagonists, (b4) cannabinoids, (b5) NK1- antagonists.
  • Component (b) of the fixed-dose combination is selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; azasetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; ondansetron and pharmaceutically acceptable salts and solvates thereof, especially its monohydrochloride dihydrate; granisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; dolasetron and pharmaceutically acceptable salts and solvates thereof, especially its monomethanesulfonate monohydrate, ramosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; tropisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; palonosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; domperidone and pharmaceutically acceptable salts and solvates thereof, especially its maleate; metoclopramide and pharmaceutically acceptable
  • the Component (b) is a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron and pharmaceutically acceptable salts and solvates thereof, in particular the mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron and pharmaceutically acceptable salts and solvates thereof, in particular the hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron
  • the Component (c) of the fixed-dose combination normally is a nsPAChA selected form the group consisting of quaternary ammonium nsPAChAs, sulfonium nsPAChAs, solifenacin and pharmaceutically acceptable salts and solvates thereof, propiverine and pharmaceutically acceptable salts and solvates thereof, oxyphencyclimine and pharmaceutically acceptable salts and solvates thereof, tolterodine and pharmaceutically acceptable salts and solvates thereof, fesoterodine and pharmaceutically acceptable salts and solvates thereof and TTS-oxybutynin and pharmaceutically acceptable salts thereof.
  • nsPAChA is advantageously selected from the group consisting of nsPAChA selected from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, butylscopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts, TTS oxybutynin; and valethamate pharmaceutically acceptable salts.
  • said nsPAChA is selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS -oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h.
  • anisotropine methylbromide; butylscopolamine bromide; cimetropium bromide; clidinium bromide; glycopyrronium bromide; methylpropiverinium iodide; methylpropiverinium bromide; otilonium bromide; prifinium bromide; timepidium bromide; trospium chloride, succinate, maleate, fumarate or tartrate; valethamate bromide; fesoterodine and its fumarate; oxyphencyclimine and its hydrochloride; propiverine and its hydrochloride; solifenacin and its succinate; tolterodine and its L-hydrogen tartrate thereof are soecificparticularly advantageous nsPAChAs used as Component (c).
  • the dose/unit form of the Component (c) may vary according to the intrinsic muscarinic cholinergic potency and to the administration route of said component.
  • said dose is from 1.2-fold to 4 times, or 1.2-fold to 6-times higher than the mean maximal tolerated dose determined in the clinical trials.
  • compositions of the present inventiom may be in unit forms, for immediate release or extended release. In such case,
  • the MCRA Component (a) is present in an amount of from 100% to 600, preferably from 120% to 600%, the maximum amount of said MCRA contained in the IR dosage unit forms administered for the approved indication contained in the commercial products or of the maximal, single MCRA dose administered during the clinical trials of each MCRA, that is considered to be equivalent to the Maximum Tolerated Dose as determined during the clinical trials;
  • Component (b) is present in an amount of from 50% to 300% of the amount of the said non- anticholinergic antiemetic agent contained as a sole active ingredient in the currently used brand or generic drugs, in particular in an amount ranging from 50% of the minimum amount to 300% of the maximum amount of said typical non-anticholinergic antiemetic agent contained in the corresponding, currently used generic or brand drug for its antiemetic indication in IR form; and
  • the nsPAChA Component (c) is present in an amount of from 50% to 600%, preferably from 1.2-fold to 6 times the maximum IR amount of said nsPAChA contained in the currently administered IR dosage unit forms indicated in the anticholinergic therapy; more particularly, the nsPAChA is present, in an IR unit form, in an amount ranging from 50% to 400%, preferably from 120% to 400%, the maximum amount of said nsPAChA contained in the currently administered IR dosage unit forms for the treatment of the above-cited disorders or, in an ER unit form, in an amount ranging from 75% to 600%, preferably from 120% to 600%, the maximum amount of said nsPAChA contained in the currently administered unit dosage IR forms or in an amount which ranging from 75% to 400% the maximum amount of said nsPAChA contained in the currently administered unit dosage ER forms for the anticholinergic therapy.
  • any one of the Components (a) may be combined with any one Component (b) and with any one Component (c) in a ternary fixed-dose combination comprising said Component (a), said Component (b) and said Component (c) in a pharmaceutical composition in dosage unit form in admixture with a pharmaceutical carrier for IR or ER administration.
  • the fixed-dose combination of the invention consists of a pharmaceutical composition in dosage unit form comprising or consisting essentially of
  • any of the MCRAs as illustrated in the above "The MCRAs" section each in a pharmaceutical composition in admixture with a pharmaceutical carrier, said MCRA being preferably selected from the group consisting of AF267 and pharmaceutically acceptable salts and solvates thereof; cevimeline and pharmaceutically acceptable salts and solvates thereof; EUK 1001 and pharmaceutically acceptable salts and solvates thereof; milameline and pharmaceutically acceptable salts and solvates thereof; RS-86 and pharmaceutically acceptable salts and solvates thereof; sabcomeline and pharmaceutically acceptable salts and solvates thereof; talsaclidine and pharmaceutically acceptable salts and solvates thereof; tazomeline and pharmaceutically acceptable salts and solvates thereof; xanomeline and pharmaceutically acceptable salts and solvates thereof;AC- 42 and pharmaceutically acceptable salts and solvates thereof; TBPB and pharmaceutically acceptable salts and solvates thereof;4-Fluoro-6-methyl-l-[l- (tetrahydr
  • any of the naAEAs as illustrated in the above "The naAEAs" section said naAEA being preferably selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; azasetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; ondansetron and pharmaceutically acceptable salts and solvates thereof, especially its monohydrochloride dihydrate; granisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; dolasetron and pharmaceutically acceptable salts and solvates thereof, especially its monomethanesulfonate monohydrate, ramosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; tropisetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; palonosetron and pharmaceutically acceptable salts and solvates thereof, especially its hydrochloride; domperidone and pharmaceutically acceptable salts and
  • nsPAChA any of the nsPAChAs as illustrated in the above "The nsPAChAs" section, said nsPAChA being preferably selected from the group consisting of anisotropine pharmaceutically acceptable quaternary salts, butyl scopolamine pharmaceutically acceptable salts, cimetropium pharmaceutically acceptable salts, clidinium pharmaceutically acceptable salts, fesoterodine and pharmaceutically acceptable salts thereof, glycopyrronium pharmaceutically acceptable salts, otilonium pharmaceutically acceptable salts, oxyphencyclimine and pharmaceutically acceptable salts thereof, prifinium pharmaceutically acceptable salts, propiverine and pharmaceutically acceptable salts thereof, solifenacin and pharmaceutically acceptable salts thereof, tolterodine and pharmaceutically acceptable salts thereof, timepidium pharmaceutically acceptable salts, trospium pharmaceutically acceptable salts and valethamate pharmaceutically acceptable salts;
  • the fixed-dose combination of the invention consists of a pharmaceutical composition comprising or consisting essentially of
  • a MCRA selected from the group consisting of cevimeline hydrochloride hemihydrate, in an amount of from 34.5 mg to 180 mg, xanomeline, as free base, as oxalate or as L-tartrate, in an amount of from 90 mg to 450 mg, milameline hydrochloride, in an amount of from 2.4 mg to 12 mg and MK 7622, as free base, as hydrochloride, as fumarate or as methanesulfonate, in an amount selected from the group consisting of from more than 5 mg to 15 mg, from more than 15 mg to 45 mg, from more than 45 mg to 270 mg, from more than 15 mg to 225 mg, from more than 45 mg to 225 mg, and from 54 mg to 180 mg;
  • a naAEA selected from the group consisting of selected from the group consisting of alosetron hydrochloride, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron hydrochloride, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron mesylate, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron hydrochloride, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron hydrochloride dihydrate, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron hydrochloride, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron hydrochloride, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg, tropisetron hydrochloride, in an amount (in tropisetron) of from 2.5 mg to 30 mg
  • nsPAChA selected from the group consisting of glycopyrronium pharmaceutically acceptable salts, in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide; propiverine and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 7.5 mg to 240 mg of propiverine hydrobromide; solifenacin and pharmaceutically acceptable salts thereof, in an amount that is equivalent to from 5 mg to 60 mg, preferably from 5 mg to 40 mg, of solifenacin succinate; trospium pharmaceutically acceptable salts, in an amount that is equivalent to from 20 mg to 480 mg of trospium chloride; and TTS-oxybutynin, in a released amount of from 3.9mg/24h to 7.8mg/24h, in admixture with a pharmaceutical carrier or vehicle.
  • glycopyrronium pharmaceutically acceptable salts in an amount that is equivalent to from 0.5 mg to 16 mg of glycopyrronium bromide
  • propiverine and pharmaceutically acceptable salts thereof in an amount that is equivalent to from
  • Component (c) is selected from the group consisting of anisotropine methylbromide, in an amount of from 25 mg to 300 mg, normally from 60 mg to 200 mg; butylscopolamine bromide in an amount of from 5 mg to 60 mg, normally from 12 mg to 40 mg; cimetropium bromide, in an amount of from 25 mg to 200 mg; clidinium bromide in an amount of from 1.25 mg to 15 mg, normally from 3 mg to 1043- mg; fesoterodine fumarate, in an amount of from 4 mg to 48 mg, normally from 9.6 mg to 32 mg; glycopyrronium bromide in an amount of from 1 mg to 12 mg, normally from 2.2 to 8 mg; otilonium bromide in an amount of from 20 mg to 240 mg, normally from 48 mg to 160 mg; prifinium bromide in an amount of from 15 mg to 180 mg, normally from 36 mg to 120 mg; propiverine hydroch
  • a particularly advantageous fixed-dose combination consists of a pharmaceutical dosage unit form comprising or consisting essentially of
  • the above patch releases xanomeline an amount/24hours giving xanomeline plasma concentrations in human of from 16.572ng/ml to 78.6ng/ml; granisetron, in an amount of from 1.5mg/24h to 5mg/24h; and oxybutynin, in an amount of from 3.9mg/24h to 5.85mg/24h.
  • said patch releases amount/24hours giving xanomeline plasma concentrations in human of from 16.572ng/ml to 78.6ng/ml; granisetron, in an amount of from 1.5mg/24h to 3mg/24h; and oxybutynin, in an amount of from 3.9mg/24h.
  • solifenacin succinate is preferably present as Component (c) in an amount selected from the group consisting of from 5 mg to 60 mg, from 10 mg to 40 mg, from 12 mg to 30 mg, from 12 mg to 25 mg and of 21 mg..
  • each of the above fixed-dose combinations may include, as a further component (d), an AChEI also formulated in a pharmaceutical composition, said AChEI being selected from the group consisting of 1,2,3,4- tetrahydro-9-acridinamine (tacrine) and pharmaceutically acceptable salts and solvates thereof, (+)-2,3-dihydro-5,6-dimethoxy-2-[[l-(phenylmethyl)-4-piperidinyl]methyl]- lH-inden-l-one (donepezil) and pharmaceutically acceptable salt and solvates thereof, (S)-N-Ethyl-N-methyl-3-[l-(dimethylamino)ethyl]-phenyl carbamate (rivastigmine) and pharmaceutically acceptable salts and solvates thereof, 4aS,6R,8aS-3-methoxy-l l- methyl-4a,5,9,10,l l,12-hexahydroxy-6
  • any of the above fixed-dose combinations and any of the pharmaceutical compositions that are part of the above combinations and kits are formulated with pharmaceutical carriers, diluents, vehicles and devices according to known and conventional methods and/or technologies in the art and as illustrated in the "The Formulations" section below.
  • any of the above fixed-dose combinations and any of the above pharmaceutical compositions may further include a component (d) an AChEI.
  • the AChEI Component (d) when included in the combination with Component (a), Component (b) and/or Component (c) as described herein, may be present in an amount of from about 100% to about 1000% of a recommended dose of Component (d) contained in a unit form used for the treatment of Alzheimer type dementia.
  • donepezil hydrochloride is present at a dose of from 5 mg to 98 mg, advantageously from 10 mg to 98 mg, preferably from 15 mg to 69 mg, normally from 15 mg to 60 mg; rivastigmine, as hydrogen tartrate, is present, in a composition for oral administration, at a dose, in rivastigmine, of from 1.5 mg to 30 mg, advantageously from 6 mg to 30 mg, preferably from 9 mg to 24 mg, normally from 9 mg to 18 mg; rivastigmine, as the free base, is present in patch releasing from 4.6mg/24h to 52mg/24h, advantageously from 9.6mg/24h to 39.9mg/24h, normally from 13.3mg/24h to 39.9mg/24h or from 4.6mg/24h to 13.3mg/24h rivastigmine; and galantamine, as hydrobromide, is present in an amount of
  • the unit form of the present invention may be a tablet, a capsule, a pre-measured volume of a liquid solution or suspension for oral administration or a TTS as a gel or patch, including spray patches, for transdermal application.
  • the nsPAChA and the MCRA, as free base are as a pharmaceutically acceptable salt or solvate thereof, may be mixed together or separated according to known technologies in admixture with a pharmaceutical carrier in a pharmaceutical composition.
  • Component (a), Component (b) and Component (c) are formulated with conventional pharmaceutical carriers in known formulations for oral use wherein said components are mixed together or separated, for example in two or three tablets introduced in a capsule or in a two-compartment capsule, wherein one of the Components (a), (b) and (c), is in a first of the two compartments and the two other Components and the second of the two compartments, or in a multilayer (di-layer or tri- layer) tablet wherein the three components are all in IR or in ER form or one or two Components is in IR form and the other(s) is/are in ER form, according to known technologies.
  • Component (d) may be optionally included in the first or second compartment, or optionally included in a multilayer tablet as described herein above, with one or more of Components (a), (b) and (c).
  • the pharmaceutical carriers and vehicles are those commonly used for the preparation of compositions for oral, buccal, including sublingual, and parenteral, in particular transdermal, administration.
  • Appropriate unit forms comprise the oral forms such as tablets, including orodispersible tablets and orosoluble tablets, soft or hard gelatin capsules, powders or granulates in sachets and suitably measured oral solutions or suspensions as well as transdermal therapeutic systems such as patches for transdermal administration.
  • Component (a), Component (b) and Component (c) may also be present in form of one of their complexes with a cyclodextrin, for example oc-cyclodextrin, ⁇ - cyclodextrin, ⁇ -cyclodextrin, 2-hydroxypropyl- -cyclodextrin or methyl- ⁇ -cyclodextrin.
  • a cyclodextrin for example oc-cyclodextrin, ⁇ - cyclodextrin, ⁇ -cyclodextrin, 2-hydroxypropyl- -cyclodextrin or methyl- ⁇ -cyclodextrin.
  • Component (a), Component (b) and Component (c), with optionally a further Component (d), may also be formulated in the form of microcapsules, optionally with one or more carriers or additives.
  • Component (a), Component (b) and Component (c), with optionally a further Component (d), together or separately, are formulated by mixing the active ingredient with conventional pharmaceutical acceptable carriers enabling said active ingredients to be formulated in tablets, dragees, orally disintegrating tablets, capsules, liquid solutions or suspensions, syrups and the like.
  • Carriers for IR tablets may include, but are not limited to, starches, cellulose and derivatives thereof; lubricants such as talc, stearic acid or magnesium stearate; diluents such as talc, powdered cellulose, lactose, starches such as maize or corn starch, mannitol, sorbitol; disaggregating agents such as microcrystalline cellulose or crospovidone; lubricants such as polyethylene glycol or magnesium stearate; ligands such as methylcellulose, sodium carboxymethylcellulose, alginic acid, alginates; sweeteners, such as sucrose, dextrose, mannitol, saccharin; or flavoring agents such as natural or synthetic oils.
  • lubricants such as talc, stearic acid or magnesium stearate
  • diluents such as talc, powdered cellulose, lactose, starches such as maize or corn starch, mannitol,
  • Carriers for orally disintegrating tablets may include, but are not limited to, lubricants, aggregating, sweetening, flavoring or disaggregating agents as well as agents improving the buccal mucosa absorption of Component (a), Component (b) and Component (c) such as sorbitol, mannitol, lactose and cellulose.
  • Carriers for liquid, normally aqueous, suspensions or solutions may include, but are not limited to, antioxidants, such as sodium metabisulfite or sodium sulfite, thickening agents, such as microcrystalline cellulose, hydroxypropylcellulose, carboxymethylcellulose or polyvinylpyrrolidone, preservatives such as methyl paraben, ethyl paraben, sodium ethylenediaminotetracetate, sodium benzoate or an alkaline salt of sorbic acid, as well as flavoring and sweetening agents.
  • antioxidants such as sodium metabisulfite or sodium sulfite
  • thickening agents such as microcrystalline cellulose, hydroxypropylcellulose, carboxymethylcellulose or polyvinylpyrrolidone
  • preservatives such as methyl paraben, ethyl paraben, sodium ethylenediaminotetracetate, sodium benzoate or an alkaline salt of sorbic acid, as well as flavoring and sweetening agents.
  • the sweeteners contained in the orally disintegrating tablets and the liquid suspensions or solutions may be natural, optional reduced sugars such as sucrose, dextrose, xylitol, mannitol or sorbitol, or synthetic product such as sodium saccharine or aspartame.
  • the flavoring agents are pharmaceutically acceptable flavors and tastes of synthetic and natural oils, the latter extracted from plants, leaves, flowers, fruits and their combinations, which include, but are not limited to, cinnamon, peppermint, anise and citron leaves, bitter almond, or citrus fruits, in particular orange and/or lemon, linden and grapefruit oils.
  • chocolate, vanilla or eucalyptus flavor and essences of fruit, in particular apple, pear, peach, strawberry, cherry, apricot, orange, lemon and/or grapes may be advantageously used.
  • composition according to the present invention may be in form of a capsule containing two tablets as described herein above, one of them comprising Component (a), and the other comprising Component (b) and Component (c) in admixture with each other and with a pharmaceutical carrier.
  • the unit form may also be a capsule containing two tablets as described herein above, one of them comprising Component (b), and the other comprising Component (a) and Component (c) in admixture with each other and with a pharmaceutical carrier.
  • the unit form may also be a capsule containing two tablets as described herein above, one of them comprising Component (c), and the other comprising Component (a) and Component (b) in admixture each other and with a pharmaceutical carrier.
  • the unit form may also be a capsule containing three tablets as described herein above, one of them comprising Component (a), the second comprising Component (a) and the third comprising Component (c) in admixture with each other and with a pharmaceutical carrier.
  • Component (d) may be optionally included in the composition as described herein above, with one or more of Components (a), (b) and (c).
  • the combination may be formulated in tablets in which one or both of the two components is in controlled-release formulation, for example as a dispersion of said component in hydroxypropylmethyl cellulose or in a film-coated microgranule.
  • the MCRA, in an ER-formulation is in the core and the nsPAChA and the naAEA, in IR-formulation, are in the outer layer in multi-layer tablets in which, for example, both the core and the outer layers are coated with a film.
  • capsules made of two separated compartments, one containing Component (a), in IR- or ER-formulation and the other containing Component (b) and Component (c), in ER- or, preferably, in IR formulation, may be used.
  • Component (d) may be optionally included in the combination as described herein above, with one or more of Components (a), (b) and (c).
  • Carriers and vehicles for ER tablets may include, but are not limited to, retardant materials such as acrylic and methacrylic acid polymers and copolymers; cellulose derivatives such as hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, or sodium carboxymethylcellulose; gums; waxes; glycerides or aliphatic alcohols or a mixture thereof.
  • Component (a), Component (b) and Component (c), with optionally a further Component (d), as the base thereof or as a pharmaceutically acceptable salt thereof, may also be formulated, together or separately in any TTS such as a patch, a gel, a cream, a spray, an ointment, a lotion or a paste.
  • Component (a) or Component (b) or Component (c) is present in admixture with the common diluents and permeation enhancers for the TTS administration; or Component (a) and Component (c) are both present in admixture with the common diluents and permeation enhancers for the TTS administration; or the Component (a) and Component (c) are both present in admixture with the common diluents and permeation enhancers, or Component (a), Component (b) and Component (c) are altogether present in admixture with the common diluents and permeation enhancers.
  • Component (d) may be optionally included in the TTS as described herein above, with one or more of Components (a), (b) and (c).
  • the permeation enhancer may be any compound which allows the improved permeation of drugs through the skin (see for example the review in Pharmaceutical Technology, November 1997, pages 58-66, the disclosure of which is herein incorporated by reference in its entirety).
  • Such substances may include, but are not limited to, be lower (Ci-C 4 ) alkanols; fatty alcohols such as lauryl alcohol (dodecanol), alone or in combination with a lower alkanol; fatty acids such as linolenic acid or oleic acid; fatty acid esters such as isopropyl palmitate, stearate, linoleate, oleate or myristate; glycerol; glycerol monoesters such as glycerol monostearate, monolinoleate or monooleate; glycerol diesters; glycerol triesters such as triacetin; sucrose monostearate, monolinoleate or monooleate; sorbit
  • permeation enhancers are present in an amount from 0.01 to 20% by weight of the total weight of the composition, advantageously in an amount of from 0.05 to 10% by weight, preferably from 0.1 to 5% by weight.
  • the oxybutynin TTS for use according to the present invention may be in any oxybutynin delivering transdermal pharmaceutical form, such as a patch, a gel, a cream, a spray, an ointment, a lotion or a paste, wherein oxybutynin is present in admixture with the common diluents and permeation enhancers, said pharmaceutical form containing oxybutynin base or a pharmaceutically acceptable salt thereof, such as its hydrochloride, hydrobromide, sulfate, phosphate, mesilate, acetate, maleate, succinate, lactate, citrate, hydrogen tartrate, tartrate, napsilate or embonate.
  • oxybutynin delivering transdermal pharmaceutical form such as a patch, a gel, a cream, a spray, an ointment, a lotion or a paste
  • oxybutynin is present in admixture with the common diluents and perme
  • Appropriate permeation enhancers are for example the aforementioned ones, and are present in an amount from 0.01 to 20% by weight of the total weight of the composition, advantageously in an amount of from 0.05 to 10% by weight, preferably from 0.1 to 5% by weight.
  • the oxybutynin TTS is a patch releasing 3.9-5.85 mg/day of oxybutynin, administered in combination, for example, with oral ondansetron (as hydrochloride dihydrate) and a MCRA.
  • oral ondansetron as hydrochloride dihydrate
  • MCRA oral ondansetron
  • Another advantageous combination is an oxybutynin patch delivering 3.9 mg/day of oxybutynin and an oral or transdermal granisetron (as the freebase or as hydrochloride), at a dose of from 1 mg to 3.1 mg and with a MCRA.
  • a routine treatment can be made with a combination of an oxybutynin patch delivering 3.9 mg/day of oxybutynin and an oral ondansetron (as hydrochloride dihydrate, at a dose of from8 mg to 32 mg and a MCRA.
  • a TTS consisting of a patch is obtained as described for example in US 5,212,199, US 5,227,169, US 5,747,065, US 6,743,441, US 7,081,249, US 7,081,250, US 7,081,251, US 7,081,252, US 7,087,241, US 2004/0057985 US 8,420,117, US 2014/0271796, US 8,802,134, US 8,877,235, the disclosures of which are each incorporated herein by reference in their entirety.
  • a TTS in form of a patch is manufactured by mixing a predetermined amount of oxybutynin, of rivastigmine or of an association of the two drugs with the aforementioned permeation enhancer in a laminated composite which basically contains at least one reservoir comprising a adhesive which is a pressure- sensitive adhesive suitable for the contact with the skin, a backing layer and a strip to be removed just before the application of the patch on the subject's skin.
  • the oxybutynin TTS may be manufactured according to one of the methods illustrated in the above- cited patent documents.
  • Component (a), Component (b) and Component (c) may be administered concurrently or sequentially to a patient suffering from a hypocholinergic disorder of the CNS such as Alzheimer type dementia and schizophrenia.
  • Component (a), Component (b) and Component (c) can be administered in a specific dosage regimen as illustrated above - to treat Alzheimer type dementia and schizophrenia, Component (a), Component (b) and Component (c) being administered simultaneously or sequentially to one another, in each case by the same or different administration route.
  • Component (a), Component (b) and Component (c) act synergistically to allow for the safe administration of high doses of Component (a) without dangerous adverse effects linked to the peripheral cholinergic action of said Component (a). Accordingly, - the therapeutic efficacy of Component (a) to safely improve cognition of patients suffering from a hypocholinergic disorder of the CNS such as Alzheimer type dementia or schizophrenia is enhanced, due to the synergistic antiemetic/peripheral anticholinergic action of Component (b) and Component (c).
  • the present invention in one aspect, provides a combination comprising or consisting essentially of, as Components:
  • MCRA muscarinic cholinergic receptor agonists
  • nsPAChAs non-selective, peripheral anticholinergic agents
  • nsPAChA used as Component (a) their properties and doses are described in the "nsPAChAs" section above.
  • Component (a), Component (b) and Component (c), together or separately, are formulated in pharmaceutical compositions prepared as described in the "Formulation" section above.
  • the present invention in another aspect, provides a method for treating a hypocholinergic disorder of the CNS, which comprises administering to a patient in need of said treatment a combination comprising or consisting essentially of, as Components:
  • MCRA muscarinic cholinergic receptor agonists
  • nsPAChAs non-anticholinergic antiemetic agent
  • nsPAChAs non-selective, peripheral anticholinergic agents
  • the method is carried out by administering Component (a), Component (b) and Component (c) of said combination concurrently, or sequentially.
  • Component (a), Component (b) and Component (c) may be independently administered by oral or parenteral route, in particular by intramuscular or intravenous injection or by transdermal administration by a TTS such as a gel or a patch.
  • MCRAs used as Component (a) their properties and doses are described in the "MCRAs" section above.
  • naAEA used as Component (b), their properties and doses are described in the "naAEAs section" above.
  • nsPAChA used as Component (c) their properties and doses are described in the "nsPAChAs section" above.
  • Component (a), Component (b) and Component (c), together or separately, are formulated in pharmaceutical compositions prepared as described in the "Formulation" section above.
  • Component (a), Component (b) and Component (c), in admixture with a pharmaceutical carrier or vehicle may be associated in the same pharmaceutical composition, formulated as described in "The Formulations" section above, in a unit dose for oral or parenteral, including transdermal, route, according to known or conventional methods or technologies in the art.
  • the doses of the above dose-ranges are given in order to present the possibility of manufacturing pharmaceutical compositions and of administering said doses in said pharmaceutical composition.
  • the discovery of the beneficial competitive antagonist/agonist action of the nsPAChA and of the MCRA, combined with a nsPAChA/naAEA synergism, enables the full efficacy of the MCRA.
  • vehicle vehicle
  • xanomeline a representative muscarinic agonist
  • mice were placed individually in cages without any bedding materials. During the experiment the number of fecal pellets were counted at different time-points, starting one hour before the time of the administration of the test compound (TO), as outlined below:
  • mice were placed individually in cages without any bedding materials. During the experiment the number of fecal pellets was counted at different time-points as outlined below:
  • T30 min administration of vehicle or xanomeline.
  • T 30min to T 2.5h counting of accumulated fecal pellets excreted.
  • T+2.5h to T+4.5h counting of accumulated fecal pellets excreted.
  • Results showed that oxybutynin dose-dependently antagonized the diarrhea induced by xanomeline, thus confirming that the representative nsPAChA oxybutynin suppresses the adverse effects of the representative muscarinic antagonist xanomeline.
  • T-maze continuous alternation task (T-CAT) is useful as model for studying compounds with cognitive enhancing properties.
  • the T-maze consists of 2 choice arms and 1 start arm mounted to a square center. Manual doors are provided to close specific arms during the force choice alternation task.
  • mice were treated with either vehicle or one of 4 doses of xanomeline:
  • mice were randomly assigned to one of the different experimental treatment groups. Each animal was identified by its group name, cage number, series (day) of experiment, and number (1 to 10) written with permanent ink on the tail.
  • the T-maze apparatus is made of gray Plexiglas with a main stem (55 cm long x 10 cm wide x 20 cm high) and two arms (30 cm long x 10 cm wide x 20 cm high) positioned at 90 degree angle relative to the main stem.
  • a start box (15 cm long x 10 cm wide) is separated from the main stem by a guillotine door. Horizontal doors are also provided to close specific arms during the force choice alternation task.
  • the experimental protocol consisted of one single session, which started with 1 "forced- choice” trial, followed by 14 "free-choice” trials.
  • animals were confined for 5 seconds to the start arm and then were released while either the left or the right goal arm was blocked by the horizontal door. Animals then negotiated the maze, eventually entering the open goal arm, and returned to the start position. Immediately after the return of the animals to the start position, the left or right goal door was opened and the animals were allowed to choose freely between the left and right goal arm ("free choice trials). An animal was considered as having entered in arm when it placed its four paws in the arm. A session was terminated and animals were removed from the maze as soon as 14 free-choice trials had been performed or 10 min had elapsed, whichever event occurred first.
  • the apparatus was cleaned between each animal using 40% ethanol. Urine and feces were removed from the maze. During the trials, animal handling and the visibility of the operator was minimized as much as possible.
  • the percentage of alternation over the 14 free-choice trials was determined for each mouse and was used as an index of working memory performance. This percentage is defined as entry in a different arm of the T-maze over successive trials (i.e., left-right- left-right, etc).
  • Results showed a dose-dependent increase in performance in the T-maze in animals treated with i.p. xanomeline. At the higher dose, however, animals were too sick to perform the test. Pretreatment with i.p. oxybutynin restored the animals' ability to perform the T-maze test.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une combinaison d'un agoniste des récepteurs cholinergiques muscariniques, d'un agent antiémétique non anticholinergique et d'un agent anticholinergique périphérique non sélectif pour le traitement de troubles hypocholinergiques du système nerveux central.
EP16845102.9A 2015-09-11 2016-09-09 Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central Withdrawn EP3347012A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217081P 2015-09-11 2015-09-11
US201662351382P 2016-06-17 2016-06-17
PCT/US2016/050907 WO2017044714A1 (fr) 2015-09-11 2016-09-09 Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central

Publications (2)

Publication Number Publication Date
EP3347012A1 true EP3347012A1 (fr) 2018-07-18
EP3347012A4 EP3347012A4 (fr) 2019-04-17

Family

ID=58240063

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16845102.9A Withdrawn EP3347012A4 (fr) 2015-09-11 2016-09-09 Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central

Country Status (3)

Country Link
EP (1) EP3347012A4 (fr)
CA (1) CA2996719A1 (fr)
WO (1) WO2017044714A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
UA128017C2 (uk) 2018-09-28 2024-03-13 Каруна Тереп'Ютікс, Інк. Композиція і спосіб лікування розладу, що послаблюється активацією мускаринових рецепторів (варіанти)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
BR122016020433A2 (pt) * 2012-09-05 2019-08-27 Chase Pharmaceuticals Corp combinação farmacêutica e uso de um nspacha e de um achei e, opcionalmente, de um naaea
EP3265067A4 (fr) * 2015-03-06 2018-09-12 Chase Pharmaceuticals Corporation Système thérapeutique transdermique constitué de combinaisons d'oxybutynine et de xanoméline
CA2978201A1 (fr) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Utilisation de formulations transdermiques d'oxybutynine pour reduire les effets secondaires associes aux agonistes muscariniques
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
US20180250270A1 (en) * 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2017147104A1 (fr) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Combinaisons d'antagoniste muscarinique m2

Also Published As

Publication number Publication date
CA2996719A1 (fr) 2017-03-16
EP3347012A4 (fr) 2019-04-17
WO2017044714A1 (fr) 2017-03-16

Similar Documents

Publication Publication Date Title
US10307409B2 (en) Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
US9913836B2 (en) Anticholinergic neuroprotective composition and methods
US10548855B2 (en) Memantine combinations and use
WO2017147104A1 (fr) Combinaisons d'antagoniste muscarinique m2
WO2018039159A1 (fr) Combinaison d'antagoniste de m2 muscarinique
EP3347011A1 (fr) Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
EP3265466A1 (fr) Combinaison contenant un anticholinergique périphérique et un agoniste muscarinique
EP3347012A1 (fr) Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
US10596139B2 (en) Oxybutynin transdermal therapeutic system muscarinic agonist combination
WO2017015349A1 (fr) Combinaison muscarinique d'un antagoniste sélectif du récepteur m2 et d'un antagoniste non sélectif périphérique pour le traitement de troubles hypocholinergiques
KR19990045728A (ko) 운동이상증에 대한 ５-ｈｔ３ 수용체 길항제

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180404

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031435000

Ipc: A61K0031216000

A4 Supplementary search report drawn up and despatched

Effective date: 20190318

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/454 20060101ALI20190312BHEP

Ipc: A61K 45/06 20060101ALI20190312BHEP

Ipc: A61K 31/216 20060101AFI20190312BHEP

Ipc: A61K 31/517 20060101ALI20190312BHEP

Ipc: A61K 31/4439 20060101ALI20190312BHEP

Ipc: A61K 31/4178 20060101ALI20190312BHEP

Ipc: A61K 9/70 20060101ALI20190312BHEP

Ipc: A61P 25/24 20060101ALI20190312BHEP

Ipc: A61K 31/166 20060101ALI20190312BHEP

Ipc: A61P 25/28 20060101ALI20190312BHEP

Ipc: A61P 25/18 20060101ALI20190312BHEP

Ipc: A61P 25/00 20060101ALI20190312BHEP

Ipc: A61P 25/14 20060101ALI20190312BHEP

Ipc: A61K 31/439 20060101ALI20190312BHEP

Ipc: A61P 43/00 20060101ALI20190312BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230310